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 Diabetic patients are more susceptible to ischemia/reperfusion injury and cardiac 
dysfunction likely due alterations in mitochondrial calcium handling.  The purpose of this 
work was to determine if redox-dependent changes in permeability transition pore 
opening and mitochondrial calcium transients contribute to augmented injury and 
dysfunction in diabetic hearts. Langendorff-perfused streptozotocin-induced diabetic 
hearts were more susceptible to ischemia/reperfusion injury, with infarct sizes of 60+4% 
of the area-at-risk (vs. 46+2% in non-diabetics; P<0.05). Administration of 5uM NIM811 
(non-immunosuppressive derivative of cyclosporine A), 1nM Bendavia (mitochondria-
targeted antioxidant) or 1 uM Minocycline (blocker of mitochondrial Ca influx) at the 
onset of reperfusion reduced diabetic infarct sizes (P<0.05).  Mitochondria isolated from 
the left ventricles of diabetic rats displayed greater sensitivity to Ca-induced 
permeability transition pore opening (P<0.05).  Mitochondrial Ca uptake was slower in 
diabetic when compared to non-diabetic mitochondria (P<0.05), and Na/Ca exchange 
activity was faster in diabetic when compared to non-diabetic, despite no differences in 
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respiratory control ratio and mitochondrial membrane potential between groups. 
Treatment of diabetic mitochondria with 2mM of the reducing agent dithiothreitol 
significantly decreased the sensitivity to PTP opening and normalized mitochondrial 
calcium uniporter activity to non-diabetic levels. These findings suggest that the 
augmented susceptibility to injury and enhanced cardiac dysfunction in the diabetic 
heart is mediated by redox-dependent shifts in mitochondrial calcium handling, and that 
three novel mitochondria-targeted compounds administered at reperfusion may be 
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Chapter 1 
The Physiological and Pathological Role of Mitochondrial Calcium  
in the Diabetic Heart 
Introduction  
 Worldwide, an estimated 220 million people suffer from diabetes, and this 
number is expected to more than double within the next two decades (83).  In the 
United States, eight percent of the population is diabetic, and nearly 80 million 
individuals are considered to be pre-diabetic (84).  The rising population of diabetics 
(particularly in areas such as eastern North Carolina) has resulted in an enormous 
economic impact, with the total costs associated with diabetes nearing a staggering 
$200 billion annually (84).  The fiscal crisis associated with diabetes is largely due to the 
host of health complications experienced by these individuals.  In particular, diabetic 
patients are at an increased risk for developing heart disease (31) and are four times 
more likely to die following a myocardial infarction than non-diabetics (153).  Moreover, 
hyperglycemia independently increases the risk for mortality (220).   
 In addition to the increased risk for mortality following myocardial infarction, 
diabetic patients experience cardiac dysfunction, independent of coronary artery 
disease or hypertension.  As early as the 1970s, investigators observed that some 
diabetic patients suffering from heart failure had no sign of coronary artery disease or 
hypertension (98, 193).  This generalized condition was termed diabetic cardiomyopathy 
by Rubler and colleagues (193), and presently includes a number of characteristic 
manifestations, including: systolic dysfunction and diastolic dysfunction, left ventricular 
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hypertrophy, impaired contractile reserve, as well as interstitial fibrosis [reviewed in 
(30)]. 
 The mechanisms responsible for the increased incidence of cardiac dysfunction 
and enhanced propensity for death following myocardial infarction in diabetics are not 
clearly understood.  However, insight provided by this work will shed light on these 
mechanisms and may promote the development of novel therapeutic strategies seeking 
to improve cardiac function and decrease the likelihood of heart failure in diabetic 
patients.  Among the candidate mechanisms, a growing body of literature indicates that 
alterations in mitochondrial function may be responsible for the increased cardiac 
dysfunction and propensity for death observed in diabetes [reviewed in (30, 41)]. 
Specifically, diabetic heart mitochondria display enhanced susceptibility to opening of 
the mitochondrial permeability transition pore (PTP) in both humans (8) and animal 
models (23, 174, 232), alterations in substrate utilization (43, 109), decreased metabolic 
enzyme activity (80), depressed respiration (7, 80, 131), altered calcium handling (80, 
181, 215) and increased reactive (ROS) production (32, 45, 128, 234) coupled with a 
decreased capacity to buffer ROS (5, 148, 237).  Chapters 2 and 3 of this work will 
provide insight into the mechanisms underlying the increased susceptibility to death 
following myocardial infarction and the impaired cardiac dysfunction observed in 
diabetic hearts, respectively. 
Models of Diabetes 
 To date, there have been few studies directly investigating the effects of diabetes 
on mitochondrial function in the human heart (7, 8), likely due to the difficulty in 
obtaining adequate human cardiac tissue samples.  Recently, Anderson et al. were the 
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first to demonstrate attenuated mitochondrial respiratory capacity in the presence of 
increased H2O2 production in permeabilized fibers from human atrial tissue (7).   The 
majority of mechanistic studies have involved the use of animals such as db/db (leptin 
receptor mutation) or ob/ob mice (leptin deficient), zucker diabetic fatty rats (leptin 
receptor mutation), or streptozotocin (STZ)-induced diabetic rats. Most studies have 
been conducted using the STZ-induced model of diabetes due to the comparability to 
humans and other animal models of diabetic cardiomyopathy as well as the ease of 
diabetes induction (42).  Similar to both humans (7, 8, 193) and animal models of type 2 
diabetes [reviewed in (41)], hearts from STZ-induced diabetic rats display alterations in 
mitochondrial calcium handling (80, 215), abnormal shifts in substrate utilization (109), 
as well as enhanced oxidative stress (202, 234), characterized by increases in reactive 
oxygen species (ROS) production and a decreased capacity to buffer ROS.  
Specifically, STZ-induced diabetic heart mitochondria exhibit decreased mitochondrial 
calcium influx in the presence of impaired left ventricular function (80, 215) and an 
enhanced susceptibility to PTP opening (174).  Further, STZ-induced diabetic heart 
mitochondria display increases in fatty acid oxidation and depressed glucose oxidation 
coupled with decreased cardiac efficiency (109).     
Ischemia-reperfusion injury and the consequences of mitochondrial Ca accumulation  	   In order to understand the mechanisms by which diabetic hearts are more 
susceptible to myocardial infarction, a brief overview of ischemia-reperfusion (IR) injury 
is provided.  The first documented observation that coronary artery occlusion could lead 
to cessation of the heart beat was made in 1698 (48).  Since that time, immense 
investigation has been conducted in order to determine the mechanisms by which 
	   4	  	  
ischemia, and paradoxically reperfusion, lead to myocardial dysfunction and cellular 
injury.  Following the onset of ischemia, myocardial contractility rapidly declines and this 
is accompanied by acidic pH, arrhythmogenesis, a decline in ATP production and 
cellular overload of Na and Ca (Figure 1.1).  Irreversible cellular death begins between 
15 and 20 minutes following the onset of ischemia, with the duration of ischemia 
correlating positively with clinical infarct size (area of dead tissue) (100).  In addition, it 
is well established that infarct size is a predictor of both short- and long-term mortality 
(22, 86, 87, 105, 106).  
 While reperfusion remains the best treatment for ischemic injury, establishing 
reperfusion can lead to conditions that impair cardiac function. Following reperfusion of 
the tissue, the myocardium may experience stunning, fatal ventricular arrhythmias 
and/or post-ischemic cell death.  Stunning is characterized by prolonged post-ischemic 
dysfunction of viable cells and may last for a few days (126, 127).  In addition to 
stunning, fatal ventricular arrhythmias can ensue in early reperfusion due to 
mechanisms likely involving mitochondrial ROS production (35, 37).  
The cellular death that occurs following IR is multi-factorial.  Although many of 
the pathways are inter-related, the ‘cause of death’ for cardiac cells can include loss of 
membrane integrity, apoptosis, necrosis and autophagy [reviewed in (83)].  Our work 
presented herein will focus on the contribution of PTP-dependent IR injury, and the 
mechanisms that influence PTP opening.  During cardiac ischemia, the loss of 
energetics leads to a significant rise in cytosolic Ca as ATP-dependent Ca pumps can 
no longer sequester cytosolic Ca, but the PTP remains closed due to acidic pH.  At the 
onset of reperfusion, the now-polarized mitochondria provide a sink for the accumulated 
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intracellular Ca, while the surge of oxygen availability leads to a concomitant burst in 
mitochondrial ROS production.  Thus at the onset of reperfusion when mitochondrial Ca 
content and ROS production are high, the conditions for PTP opening are ideal, 
resulting in mitochondrially-driven apoptosis and necrosis, with potentially irreversible 
cardiac damage (96).  Of clinical interest, PTP opening has also been implicated in 
brain (50), renal (67), liver (123) and lung (59) IR injury as well as in diseases such as 
Alzheimer’s (73) and cancer (82). Furthermore, the vast majority of cardiac patients 
experiencing IR arrive in the clinic after the onset of symptoms.  Compounds that are 
effective when administered at reperfusion have enormous clinical potential.  In Chapter 
2, we provide evidence for at least two novel therapies that effectively reduce infarct 
size when given at the onset of reperfusion.   
Mitochondrial Permeability Transition Pore in the Diabetic Heart 
 The PTP is a non-selective pore that forms within the inner membrane of 
mitochondria, allowing for the exchange of molecules less than 1.5 kDa (54, 103).  The 
molecular components of the PTP are controversial, however, there appears to be an 
important role for the mitochondrial phosphate carrier (PiC) (134), and perhaps more 
importantly, the peptidly-prolyl cis-trans isomerase, cyclophilin-D (CyP-D) (216).  In 
addition, a regulatory role for the adenine nucleotide transferase (ANT) seems apparent 
(97), while knockout studies have ruled out a role for the voltage-gated anion channel 
(VDAC) (16).  Halestrap and colleagues proposed a model for the PTP (Figure 1.2) 
where the PiC and ANT may form a heterodimer in the inner membrane of 
mitochondria.  This process is proposed to be catalyzed by CyP-D and initiated during 
conditions of ischemia/reperfusion.  The opening of the PTP is favorable under 
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conditions where mitochondrial Ca is high, and the sensitivity to Ca-induced PTP 
opening is enhanced by alkaline pH, depletion of adenine nucleotides, increases in 
inorganic phosphate (Pi) and likely of most importance, oxidative stress [reviewed in 
(96)]. 	  
 Diabetic heart mitochondria exhibit an enhanced susceptibility to opening of the 
PTP in both humans (8) and animal (23, 174, 232) models of diabetes.  Therefore, it is 
logical that the increased susceptibility to PTP opening observed may be responsible for 
the increased proclivity for death following myocardial infarction in diabetes, however, 
this link has yet to be established. Oliveira and colleagues have shown that the 
probability of PTP opening in isolated diabetic heart mitochondria can be normalized to 
non-diabetic controls with direct inhibition of PTP opening utilizing cyclosporine A (CsA) 
(174), suggesting that blocking PTP opening may potentially attenuate IR injury in 
diabetic hearts. Therefore, it is plausible that inhibition of PTP opening may reduce the 
likelihood for PTP opening and provide protection against IR injury in diabetic hearts. 
Further, the mechanisms responsible for the increased susceptibility to PTP opening in 
diabetic heart mitochondria have not been revealed.  Because oxidative stress 
significantly amplifies Ca-induced PTP opening, the oxidative shift in redox state 
characteristic of the diabetic heart may explain the increased proclivity for PTP opening.  
Chapter 2 will describe how a reductive shift in redox state can decrease the sensitivity 
to PTP opening in isolated diabetic heart mitochondria.   
Pharmacological Inhibition of PTP Opening by Targeting Cyclophilin-D 
 Because PTP opening is a distinctive feature of IR injury, chemical inhibitors that 
prevent/delay PTP opening show promise in protecting against injury.  Strategies that 
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target CyP-D have been frequently employed to inhibit PTP opening due to the notion 
that specific targeting of ANT and/or PiC would be deleterious to bioenergetic function.  
To date, a preponderance of studies have inhibited PTP opening by utilizing 
pharmacologic or genetic ablation approaches targeting CyP-D.  A number of studies 
have indicated that inhibition of CyP-D with cyclosporine A (CsA) can decrease the 
probability of PTP opening and attenuate several indices of myocardial IR injury, 
including: infarction (10, 11, 101, 154, 228), left ventricular dysfunction (91, 102, 172), 
cardiomyocyte death (124, 165) and mitochondrial dysfunction (70, 173).   
 In a recent clinical trial (182), the use of CsA at the time of reperfusion reduced 
infarct size in humans by approximately 30% (when assessed by MRI), corroborating 
previous data from animal studies.  Although promising, the use of CsA is confounded 
by a narrow therapeutic window (165), potentially harmful effects to the 
microvasculature (180, 214, 231), deleterious effects on long-term myocardial function 
(132), suppression of mitochondrial respiration (11), lack of protection against 
arrhythmia (4, 34), immunosuppression (15) and nephrotoxicity (163).  Because of 
these potential adverse effects, the use of CsA should be particularly avoided in 
diseased populations that may be susceptible to these conditions.  For example, 
diabetic patients experience depressed immune function (157) as well as high rates of 
kidney failure (2, 188).  In fact, diabetes is the leading cause of renal failure (2).  Due to 
the immunosuppressive and nephrotoxic effects of CsA, its use in the diabetic 
population would likely be precluded. 
 NIM811 is a non-immunosuppressive derivative of CsA developed by Novartis, 
and unlike CsA, NIM811 blocks PTP formation by selectively binding matrix CyP-D and 
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not the cytosolic immunosuppressant, cyclophilin A (222). NIM811 has been shown to 
decrease infarct size and directly block Ca-induced PTP opening in intact rabbit hearts 
and isolated rabbit cardiac mitochondria, respectively (12), by specifically binding CyP-
D.  NIM811 may prove to be a useful therapeutic tool for the treatment of myocardial IR 
injury, and Chapter 2 describes our use of NIM 811 to attenuate injury in the diabetic 
heart. 
”Upstream” Inhibitors of the Mitochondrial Permeability Transition Pore 
 Given the relationship between mitochondrial Ca overload and PTP opening, 
blocking mitochondrial Ca influx can also decrease the open probability of PTP and 
decrease myocardial IR injury.  Several blockers of the MCU, namely ruthenium red 
(RR) and ruthenium 360 (Ru360) (89), have been shown to protect the heart from IR 
injury (46, 85).  However, the use of RR and Ru360 are confounded by non-specific Ca-
blocking effects (120, 192) that may impair systolic and potentially diastolic function.  
These compounds also show membrane impermeability (21, 189), which would 
decrease the likelihood of intracellular entry of the drug into target tissues.  The 
tetracycline antibiotic, minocycline, is just as effective in blocking MCU as Ru360 
(Figure 1.3).  Minocycline has been shown to diminish cardiac IR injury (190, 195) and 
has high permeability in cardiac tissue (190), making it an attractive candidate for 
protecting cardiac tissue during reperfusion by reducing mitochondrial calcium overload.  
 Due to the powerful effects of oxidative stress on enhancing PTP formation, it is 
no surprise that scavengers of free radicals (24, 146, 185, 197) have been shown to 
decrease the likelihood of PTP opening and provide protection.  An investigation by 
Rajesh et al. revealed a significant decrease in myocardial infarct size in rats that 
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received the antioxidant MCI-186 30 minutes prior to a 30-minute ischemic insult (185).  
Other studies have employed the use of Mn superoxide dismutase (MnSOD) mimetics 
such as M40403 (146) and SC-52608 (24), each of which decreased myocardial IR in 
vitro and in vivo, respectively.  Investigators have also utilized glutathione (GSH) (197) 
or the GSH precursor, N-acetyl cysteine (NAC), (68) and observed decreases in IR 
injury.  While these data are promising, antioxidants have provided disappointing 
outcomes in clinical patients (3, 79, 140, 159, 240).  Because the chief site of 
intracellular ROS production is within the mitochondria (213), antioxidants that target 
mitochondria would provide the greatest efficacy in reducing ROS during times such as 
IR when the ROS burden is high.  A recent review by Murphy and Smith discusses the 
potential use of antioxidants conjugated to the lipophilic cation triphenylphosphonium 
(TPP+) (161).  The lipophilic and cationic properties of TPP+ would allow the conjugated 
antioxidants to penetrate biological membranes and accumulate in mitochondria, but 
one limitation to their use is that uptake is based on mitochondrial membrane potential, 
which may be collapsed in early reperfusion (when the drug uptake is needed the most).   
 Recently, the antioxidant peptide Bendavia (SS31 in the literature) has been 
shown to attenuate myocardial IR injury (49). Bendavia has been shown to diminish 
ROS in several tissues (205), and has the unique property of targeting to mitochondria 
whether they are polarized or not (H Szeto, unpublished observations). Thus, Bendavia 
would provide efficient scavenging at the source of greatest ROS production (213).  Our 
group has shown that administration of Bendavia at reperfusion (across a wide 
concentration spectrum) provides protection against IR injury (Figure 1.4).  
Preconditioning as a Method of Protection in Ischemia-Reperfusion Injury 
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 A large number of agents can reduce injury when given before ischemia, a 
general phenomenon called cardiac preconditioning.  Preconditioning tissue with 
several sub-lethal bouts of ischemia before a long ischemia can reduce myocardial IR 
injury [first described in 1986 by Murry et al. (162)].  These investigators found that four 
cycles of five minutes of ischemia and five minutes of reperfusion immediately prior to a 
40-minute ischemic insult in dogs could provide cardioprotection (measured by a 25% 
decrease in infarct size) when compared to non-preconditioned hearts.  The 
cardiprotection provided by preconditioning was not accompanied by differences in 
coronary flow, suggesting that other cellular mechanisms were responsible for the 
cardioprotective effect.  There are two windows of protection afforded by 
preconditioning [reviewed in (113, 160, 207, 238)].  The first window of protection 
appears to be within one hour following the initiation of the first preconditioning ischemic 
episode, while the second window of protection appears to be approximately 24 hours 
following preconditioning.  While the second window of protection appears to be due to 
alterations in gene expression and protein synthesis, the first window of protection is too 
short for such adaptations to take place.  Therefore, it is widely accepted that the 
cardioprotection afforded by first-window preconditioning is due to changes in cellular 
signaling pathways (see previous reviews on preconditioning), some of which may 
involve down regulation of PTP (111).   
 Complimenting studies that demonstrate ischemic preconditioning can protect 
against IR injury, several studies have shown that a variety of drugs when given before 
an ischemic insult can provide protection (26, 27). Among the large number of 
pharmacological preconditioning agents, anesthetic-induced preconditioning (with 
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inhalants) is observed in a variety of tissues (20, 61, 116, 119, 183, 225) and in species 
ranging from laboratory mice (151), rats (119, 141), guinea pigs (187), rabbits (92), 
dogs (152, 227) and human patients undergoing surgery (20, 116).  While the use of 
anesthesia-induced preconditioning is an unlikely candidate for the treatment of 
myocardial infarction, it does have implications for patients undergoing transplantation 
surgery, where tissues such as liver, kidney, lung and heart become ischemic.   Chapter 
4 of the current work will discuss the cardioprotective effects of the anesthetic cocktail, 
ketamine-xylazine, in isolated hearts from guinea pigs.   
Physiological Calcium Handling in the Heart 
While intracellular overload of Ca can lead to both necrosis and apoptosis (94-
96), it is well established that Ca is a key regulator of both myocardial contraction and 
the ATP producing metabolic processes that support myocardial contraction (89, 90).  
Both cytosolic (28, 76, 130) and mitochondrial (80, 181, 215) Ca handling have been 
revealed to be impaired in the diabetic heart, which could explain a portion of the 
cardiac dysfunction observed in the diabetic condition.  In order to understand how 
dysfunctional Ca handling in the diabetic heart contributes to cardiac dysfunction, a brief 
review of myocardial Ca handling is provided (Figure 1.5).  
Under physiological conditions, a small amount of extracellular Ca enters the 
cardiac myocyte down its electrochemical gradient through the L-type Ca channels in a 
process initiated by sarcolemmal depolarization.  Entry of extracellular Ca into the 
cytosol triggers the release of comparatively large quantities of Ca by the Ca-sensitive 
ryanodine receptors (RyR2) located on the sarcoplasmic reticular (SR) membrane in a 
process known as Ca-induced Ca-release.  Ca then binds to troponin C and allows for 
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the interaction of actin and myosin, initiating systole.  In order for diastole to take place, 
cytosolic Ca must return to baseline levels (~100nM).  The major routes for Ca uptake 
are the ATP-dependent sarco/endoplasmic reticulum Ca-ATPase (SERCA), 
sarcolemmal NCX and Ca-ATPase and mitochondria.  
The critical role of Ca in the myocardium does not terminate at the level of 
contraction and relaxation.  Ca is a vital activator of several key sites of NADH 
production and metabolic control within the mitochondria.  Not only does Ca enter and 
leave the cytosol on a beat-to-beat basis, but it has also been suggested to enter the 
mitochondria on a beat-to-beat basis (189).  Under physiological conditions, Ca enters 
the mitochondria down its electrochemical gradient through the mitochondrial Ca 
uniporter (MCU) (18, 64, 89) and exits in a sodium-dependent manner through the 
mitochondrial Na-Ca exchanger (mNCX) (54-56, 176) (Figure 1.6).  Nearly 40 years 
ago, Ca was shown to both directly and indirectly activate NADH producing enzymes 
such as pyruvate dehydrogenase, isocitrate dehydrogenase, and α-ketoglutarate 
dehydrogenase (66, 99, 167).  In addition to activation of NADH production, Ca can 
directly contribute to the activity of complex V of the mitochondrial electron transport 
system.  Even in the presence of NADH, the activity of the FoF1 ATPase is inhibited in 
the absence of Ca (217).  Providing support for the activation of the NADH producing 
enzymes and the ATPase, increasing mitochondrial Ca levels leads to an increase in 
ATP synthesis, while decreasing mitochondrial Ca decreases ATP synthesis (115).  
Therefore, Ca entry into mitochondria is critical to ATP production and support of 
myocardial contraction.  Due to the regulatory role of Ca for both contraction and ATP 
production, Balaban proposed the concept of “parallel activation” in myocardial supply 
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and demand matching (17).  Alterations in Ca handling could impair the ability of 
mitochondria to meet the myocardial energy demand with the appropriate supply of 
energy.  This energy mismatch can result in myocardial mechanical failure (i.e. 
depressed left ventricular ejection fraction, decreased ventricular compliance, etc.), 
thus, in such a situation, an adequate supply of nutrients may not be unable to reach 
systemic tissues.     
Due to the important role of mitochondrial Ca in ATP production (115), recent 
evidence has suggested that mitochondrial Ca handling may be altered failing hearts 
(138, 139).  A study by Liu and O’Rourke revealed that myocytes from a guinea pig 
model of heart failure had decreased levels of NADH, and treatment with CGP-37157  
(inhibitor of mNCX) significantly increased NADH.  These data suggest that an increase 
in mitochondrial Ca can improve mitochondrial bioenergetics in diseased hearts.  This 
study supports previous work (115), suggesting that maintenance of mitochondrial Ca is 
integral to ATP production and that a decrease in mitochondrial Ca can result in heart 
failure.  
Calcium Handling in the Diabetic Heart 
Interestingly, many characteristics of diabetic hearts overlap with those of heart 
failure, including both systolic (75, 193) and diastolic dysfunction (33, 198, 200) as well 
as metabolic inflexibility (38, 147, 226).  Diabetic hearts exhibit abnormal cytosolic Ca 
homeostasis, characterized by increased diastolic and/or decreased systolic Ca levels 
[reviewed in (135)].  A study by Allo et al. demonstrated that the activity of both the 
sarcolemmal Na-Ca exchanger and sarcolemmal Ca-ATPase were decreased in 
diabetic hearts (6).  In addition, a study by Ganguly and colleagues provided evidence 
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of decreased SERCA activity coupled with impaired diastolic dysfunction (84).    
Complimentary to this study, overexpression of SERCA2a (subunit of the SERCA) 
improves impairments in contractility in diabetic mice (219), suggesting that 
dysfunctional cytosolic Ca handling may contribute to the cardiac dysfunction observed 
in diabetes, and cytosolic Ca levels have been shown to influence mitochondrial Ca 
(189).  Therefore, aberrant cytosolic Ca handling observed in diabetic hearts may 
translate to changes in mitochondrial Ca.  Moreover, the overlap in the characteristics of 
failing non-diabetic hearts with those of diabetic hearts (described above) may also 
suggest that mitochondrial Ca could be altered in diabetes.  The recent observation by 
Liu and O’Rourke that mitochondrial Ca handling is altered in heart failure may translate 
to the diabetic heart.  Previous studies have suggested that mitochondrial Ca influx is 
slower in isolated mitochondria from diabetic hearts (80, 181, 215), and Chapter 3 of 
this work will provide compelling direct evidence that mitochondrial Ca influx through 
MCU and Ca efflux via mNCX are altered in isolated diabetic heart mitochondria, in the 
absence of differences in ΔΨm.   
Tanaka and colleagues demonstrated reduced Ca influx into diabetic 
mitochondria.  However, the reduced mitochondrial Ca uptake observed in diabetic 
hearts was coupled with a decrease in mitochondrial membrane potential (ΔΨm).  
Because ΔΨm is the primary driving force for mitochondrial Ca influx, a decrease in ΔΨm 
will decrease Ca influx into mitochondria.  Therefore, it is difficult to determine whether 
the difference in mitochondrial Ca influx observed in this study was solely due to 
decreased ΔΨm differences or if other factors were involved, such as altered expression 
of MCU or mNCX.  Moreover, the ΔΨm measurements were determined using the 
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lipophilic cation TPMP+ in myocytes.  When used in intact cells, the driving force for 
TPMP is a combination of mitochondrial and sarcolemmal membrane potentials.  Given 
that diabetic hearts are well-known to have lower repolarizing K+ currents (133), 
diminished TPMP uptake (as seen by Tanaka et al.) could be due to smaller 
sarcolemmal membrane potential and independent of ΔΨm. Flarsheim and coworkers 
also demonstrated a reduction in mitochondrial Ca influx in diabetic rat hearts (80).  
However, they did not measure ΔΨm in this study.  In addition, these observations were 
made using the Ca indicator, arsenazo III, which as been shown to enhance the 
production of ROS (155).  
Based on the bioenergetic importance of mitochondrial Ca, decrements in the 
activity of these mitochondrial Ca pathways may be responsible for the impaired cardiac 
function and decreased cardiac efficiency observed in both human (178, 179) and 
animal models of diabetes (31, 32). Because supply-demand mismatch is a 
distinguishing feature of clinical heart failure (60, 62, 166), it is logical that the impaired 
mitochondrial Ca handling observed in diabetes may be responsible for the cardiac 
dysfunction observed.  While there have been mechanistic studies to explain alterations 
in cytosolic Ca handling in diabetic hearts (219, 230), until this work, there has been no 
mechanistic insight into the alterations observed in mitochondrial Ca handling.  Diabetic 
heart mitochondria display an oxidative shift in redox state characterized by increased 
ROS production (32, 45, 128, 234) and a decreased capacity to buffer ROS (5, 148, 
237).  In particular, diabetic hearts display a decrease in the activity of glutathione 
peroxidase and Cu/Zn superoxide dismutase (5) as well as impairments in catalase 
activity (237).  Oxidative shifts in redox state can alter the activity of cytosolic Ca 
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handling proteins (65, 218).  For example, oxidative stress induces Ca leak from RyR2 
(65, 218) in heart failure, and this leak can be reversed with the antioxidants vitamin C 
and E (65). No laboratories have investigated the effects of the oxidative shift in redox 
state characteristic of the diabetic heart on mitochondrial Ca handling.  Chapter 3 of this 
work will provide cogent evidence that the oxidative shift in redox state characteristic of 
the diabetic heart directly impairs mitochondrial calcium handling, and this impairment 
can be normalized with a reducing agent. 
Conclusions 
 The continuously growing diabetic population exhibits signs of heart failure, 
independent of coronary artery disease and hypertension.  In addition, diabetics are 
more likely to die following myocardial infarction when compared to non-diabetics, and 
accordingly, ischemic heart disease is the leading cause of death among the rapidly 
growing diabetic population.  Animal models of diabetes also exhibit increased 
proneness for cardiac injury, characterized by heightened propensity for 
electromechanical dysfunction and cell death. Cardiac mitochondrial dysfunction has 
been recently proposed as a culprit in the enhanced susceptibility of the diabetic heart 
to failure and ischemic injury.  Specifically, diabetic heart mitochondria display 1) an 
increased propensity for PTP opening 2) impairments in mitochondrial Ca handling and 
3) an oxidative shift in redox state.  However, the impact of this shift in redox state on 
increased likelihood for PTP opening and impaired mitochondrial Ca handling has not 
been realized.  In order to develop effective therapeutic strategies designed to mitigate 
cardiac dysfunction and decrease IR injury in the diabetic heart, the underlying cellular 
mechanisms must be elucidated. 
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Central Hypothesis 
 Chapter 2 will investigate the hypothesis that increased propensity for PTP 
opening characterized by diabetic hearts is responsible for the increased myocardial IR 
injury observed. We believe that the oxidative shift in redox state characteristic of the 
diabetic heart increases the likelihood for PTP opening and impairs mitochondrial Ca 
handling in diabetic hearts.  It is further hypothesized that shifting the redox state 
towards a more reduced state will decrease the likelihood of PTP opening and improve 
mitochondria Ca handling in diabetic hearts.      
 The observations of this work support the hypotheses that 1) the increased 
susceptibility to PTP opening is responsible for the increased likelihood of myocardial IR 
injury in diabetes and 2) the oxidative shift in redox state characteristic of the diabetic 
heart is responsible for the increased propensity to PTP opening and the impaired 
mitochondrial Ca handling observed in the diabetic heart.  Insights provided by this work 
may provide invaluable preventative measures or therapeutic treatments for diabetic 









Increased Susceptibility to Mitochondrial Permeability Transition Pore  
Opening in the Diabetic Heart 
Abstract 
 Diabetic patients are more susceptible to ischemia/reperfusion (IR) injury, likely 
due to enhanced mitochondrial permeability transition pore (PTP) opening.  The 
purpose of this study was to: 1) determine if three novel mitochondria-targeted 
compounds administered at the onset of reperfusion protect diabetic hearts from injury 
and 2) determine if redox-dependent changes in PTP opening contribute to augmented 
injury in diabetic hearts. Langendorff-perfused STZ-induced diabetic hearts were more 
susceptible to IR injury, with infarct sizes of 60+4% of the area-at-risk (vs. 46+2% in 
non-diabetics; P<0.05). Administration of 5uM NIM811 (non-immunosuppressive 
derivative of cyclosporine A), 1nM Bendavia (mitochondria-targeted antioxidant) or 1uM 
minocycline (blocker of mitochondrial Ca influx) at the onset of reperfusion reduced 
diabetic infarct sizes (P<0.05). Mitochondria isolated from the left ventricles of diabetic 
rats displayed greater sensitivity to PTP opening (P<0.05).  Treatment of diabetic 
mitochondria with 2mM of the reducing agent dithiothreitol and 4 days of daily treatment 
with Bendavia significantly decreased the sensitivity to PTP opening. These findings 
suggest that the augmented susceptibility to injury in the diabetic heart is mediated by 
redox-dependent shifts in PTP opening, and that three novel mitochondria-targeted 
compounds administered at reperfusion may be suitable adjuvant reperfusion therapies 
to attenuate injury in diabetic patients.  
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Introduction 
 Presently, the United States is home to approximately 26 million diabetic 
individuals (84), and by the year 2025, it is estimated that the global population of 
diabetics will reach 300 million (125).  Diabetes significantly increases the probability of 
death following myocardial infarction (153), with hyperglycemia independently 
increasing the risk for mortality (220).  The underlying mechanisms responsible for 
augmented injury in diabetics are not clear.  This paucity in the literature provides a 
substantial barrier for the development of effective therapeutic strategies seeking to 
diminish ischemic injury in diabetic patients.  Elucidating the cellular mechanisms that 
contribute to the cardiac dysfunction and augmented ischemic injury observed in the 
diabetic condition may foster novel putative treatments for diabetic patients that 
experience myocardial infarction.   
 While the etiology for the increased risk of ischemic injury is undoubtedly multi-
factorial, a growing body of evidence suggests that aberrant mitochondrial function 
plays a significant role in the pathogenesis of the increased proclivity for death observed 
in these patients [reviewed in (41)].  Specifically, diabetic heart mitochondria exhibit an 
increased propensity for mitochondrial permeability transition pore opening (PTP) (8, 
23, 174, 232), coupled with an oxidative shift in redox state, characterized by increased 
reactive oxygen species (ROS) production (32, 45, 128, 234) and a decreased capacity 
to buffer ROS (5, 148, 237).   Mitochondrial overload of Ca can lead to the emergence 
of the mitochondrial permeability transition pore (PTP), particularly under conditions of 
oxidative stress [reviewed in (93, 95, 96)].  PTP opening results in depolarization of 
mitochondrial membrane potential (ΔΨm) and hydrolysis rather than generation of ATP, 
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followed by subsequent loss of cardiac electromechanical function and cell death.  PTP 
induction is particularly favorable during ischemia/reperfusion (IR).  During cardiac 
ischemia, the loss of energetics leads to a significant rise in cytosolic Ca as ATP-
dependent Ca pumps can no longer reduce cytosolic Ca.  At the onset of reperfusion, 
the now-polarized mitochondria provide a sink for the accumulated intracellular Ca, 
while the surge of oxygen availability leads to a concomitant burst in mitochondrial ROS 
production.  Thus at the onset of reperfusion when mitochondrial Ca content and ROS 
production are high, the conditions for PTP opening are ideal.  
 Diabetic heart mitochondria demonstrate an enhanced susceptibility to opening 
of the PTP in both humans (8) and animal models of diabetes (23, 174, 232).  It is 
certainly plausible that the increased susceptibility to PTP opening observed in the 
diabetic heart may be responsible for the increased proclivity for death following 
myocardial infarction.  However, until this investigation, that link had yet to be 
established in diabetic hearts.  Further, the mechanisms responsible for the increased 
susceptibility to PTP opening in diabetic heart mitochondria have not been revealed.  
Because oxidative stress significantly amplifies Ca-induced PTP opening, the oxidative 
shift in redox state characteristic of the diabetic heart (described above) may explain the 
increased proclivity for PTP opening.  Here, we demonstrate that directly inhibiting PTP 
opening utilizing NIM811 (non-immunosupressive derivative of CsA) and indirectly 
inhibiting PTP opening with Bendavia (novel mitochondria-targeted antioxidant) and 
minocycline (blocker of mitochondrial Ca influx) reduces infarct size in isolated diabetic 
hearts and to the same extent as drug treated non-diabetic hearts.  Further, we provide 
evidence that a reductive shift in the redox state of isolated diabetic heart mitochondria 
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decreases the sensitivity to Ca-induced PTP opening.  The observations of this work 
suggest that the increased propensity for IR injury in diabetic hearts is due to enhanced 
susceptibility to PTP opening, and the shift in redox state characteristic of the diabetic 
heart increases the likelihood for PTP opening and impairs mitochondrial Ca handling. 
Materials and Methods 
 All reagents used were of the highest grade commercially available (Sigma-
Aldrich, United States).  Calcium green 5N salt was purchased from Invitrogen 
(Carlsbad, CA, USA).     
 All animal studies were approved by the East Carolina University Institutional 
Animal Care and Use Committee and were in accordance with the principles stated in 
the Guide for the Care and Use of Laboratory Animals.  Male Sprague-Dawley rats (7-9 
weeks old) were housed in a temperature (22oC) and light-controlled (12 hour light/12 
hour dark) environment and fed standard rat chow (Research Diets, New Brunswick, 
NJ, USA) and water ad libitum.  
 After at least five days of acclimation to the facility, diabetes was induced with a 
single intraperitoneal (i.p.) injection of streptozotocin (STZ, 65 mg/kg) dissolved in 100 
mM sodium citrate (pH = 4.5) following a 12-hour overnight fast.  Control animals 
received an i.p. injection of sodium citrate.  All experiments were performed 2 weeks 
following STZ injection.  Blood glucose was determined using a commercially available 
glucometer (One Touch Ultra 2, LifeScan, Milpitas, CA, USA 
 Beating hearts were removed from anesthetized (ketamine/xylaine; 85/15 mg/kg) 
rats via bilateral thoracotomy and perfused (perfusion pressure of 75 mmHg) in a 
retrograde fashion on a modified Langendorff apparatus using an established protocol 
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previously described by our group (204).  Hearts were perfused with a modified Krebs-
Henseleit buffer containing (in mM): 118 NaCl, 24 NaHCO3, 4.75 KCl, 1.2 KH2PO4, 1.2 
MgSO4, 2.0 CaCl2, and 10 glucose (gassed with 95/5% O2/CO2).  Hearts were bathed in 
a buffer-filled perfusion chamber maintained at 37°C for the duration of the experiments. 
Following the initiation of perfusion, hearts were instrumented for the simultaneous 
observation of mechanical and electrical function.  A buffer-filled latex balloon (size 5, 
Harvard Apparatus, Holliston, MA, USA), calibrated at the beginning of each day using 
a digital manometer, was inserted into the left ventricle (via the mitral valve) for the 
measurement of left ventricular developed pressure (LVDP), with balloon volume 
adjusted to establish a diastolic pressure of 5-8 mmHg.  Three electrodes were placed 
into the buffer-filled perfusion chamber for the measurement of volume-conducted ECG.  
A pre-established protocol of electrode placement was utilized to obtain a signal 
analogous to Lead II of a typical 12-lead ECG (34, 35).  Coronary flow rates were 
monitored constantly with a flow probe (Transconic Systems, Ithaca, NY, USA) 
connected in series with the perfusion line. All physiological parameters were 
continuously monitored and stored on a personal computer using commercially 
available software (Chart, AD Instruments, Colorado Springs, CO, USA).  Heart rate 
was calculated using the LVDP trace, and maximal rates of contraction and relaxation 
(±dP/dt) were calculated using the derivative of the LVDP trace. 
 Following a 10 minute baseline period, ischemia/reperfusion was initiated 
similarly to that described previously by our group (204).  Hearts were exposed to global 
no-flow ischemia by stopping perfusion for 20 minutes.  At the end of the index 
ischemia, static buffer from the perfusion lines was washed out (via an accessory port 
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proximal to the aortic cannula), and reperfusion was allowed to ensue for 2 hours with 
or without the presence of 5 mM NIM811 [inhibitor of the PTP(11)], 1 nM Bendavia 
[mitochondrial-targeted antioxidant (210)] or 1 uM minocycline (blocker of mitochondrial 
calcium influx, Figure 1.4).  Because treatment at the start of reperfusion is most 
clinically relevant, these drugs were introduced at the start of the 2-hour reperfusion 
protocol.  At the end of reperfusion, the left ventricle was dissected, sliced into 5mm-
thick slices, incubated in 1% triphenyltetrazolium chloride (TTC) for 10 minutes (37°C) 
and digitally photographed for subsequent infarct size analysis.  TTC stained viable 
tissue bright red, while infarcted tissue appeared pale in color.  Infarct size was 
expressed as the infarcted area as a percentage of the left ventricle (calculated using 
ImageJ software, NIH, Bethesda, MD, USA).  Arrhythmias were scored as described 
previously by our group (34, 35, 204) and were in accordance with the Lambeth 
Conventions (57, 223). Arrhythmias were scored during the reperfusion period as 
follows: 0 = 0 – 49 ventricular premature beats; 1 = 50 – 499 ventricular premature 
beats; 2 = > 499 ventricular premature beats and/or 1 episode of spontaneously 
reverting ventricular tachycardia (VT) or ventricular fibrillation (VF) less than 60 sec in 
total duration; 3 = > 1 episode of VT or VF that is < 60 sec total duration; 4 = reverting 
VT or VF or both that is < 120 s in total duration; 5 = VT or VT or both that is > 120 sec 
in combined duration; 6 = non-reverting (fatal) VT or VF that began > 15 min after 
reperfusion; 7 = fatal VT/VF that began between 5 min and 15 min after reperfusion; 
8 = fatal VT/VF that began less than 5 min after reperfusion.   
 Cardiac mitochondria were isolated from the left ventricle of hearts utilizing a 
protocol similar to Boehm et al. (25).  For the mitochondrial isolation, all steps were 
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performed at 4°C, and all instruments for the procedure were chilled overnight prior to 
the isolation at 4°C.  Rat hearts were excised from anesthetized rats (as described 
above) and immersed in 10 mL ice-cold isolation solution (IS) containing (in mM): 300 
sucrose, 10 sodium-hepes and 0.2 EDTA. The left ventricle was isolated, weighed, and 
rinsed in fresh IS buffer.  Hearts were minced into 2-3 cm3 cubes and subjected to 2 
minutes of digestion using 1.25 mg trypsin, diluted in 10 mL of IS (pH = 7.2).  Following 
digestion, 6.5 mg of trypsin inhibitor was added, diluted in 10 mL IS buffer + BSA 
(1mg/mL) at pH = 7.4.  Tissue was resuspended in 10 mL IS buffer + BSA and 
homogenized with a teflon Potter-homogenizer.  The homogenate was centrifuged at 
600g for 10 minutes, and the supernatant was then centrifuged at 8000g for 15 minutes.  
The supernatant was discarded, and the pellet re-suspended in 10 mL IS buffer + BSA.  
This step was repeated one more time, and the final pellet was stored on ice in ~150 mL 
IS buffer.  Mitochondrial protein content was determined using a BCA protein assay.  
 To determine the quality of our mitochondrial preparations, respiratory control 
ratios (RCR) were measured using a Clark-type micro-oxygen electrode 
(Microelectrodes, Bedford, NH, USA).  Reactions were conducted in a closed, 
magnetically stirred chamber in 2.5 mL mitochondria assay buffer containing (in mM): 
125 KCl, 5 HEPES, 2 K2PO4, 1 MgCl2 and 0.5 mg mitochondria (25o C, pH = 7.3).  
Following a two-minute equilibration period, mitochondria were energized with 5 mM 
glutamate/5 mM malate to initiate state 2 respiration.  State 3 respiration was initiated 
with the addition of 2.5 mM ADP.  RCRs were calculated by dividing the state 3 
respiration by the state 2 respiration.   
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 Mitochondria (0.75 mg) were suspended in mitochondria assay buffer (described 
above) and supplemented with the fluorescent probe 1 µM calcium green 5N salt (Ex = 
506 nm, Em = 532) to track changes in extramitochondrial calcium.  Fluorescence was 
measured using a spectrophotometer (Photon Technology International, Birmingham, 
NJ, USA). Calcium-induced permeability transition pore (PTP) opening experiments 
were performed under state 2 conditions. Mitochondria were energized with 5 mM 
glutamate/5 mM malate.  Mitochondrial permeability transition pore opening was 
induced by subjecting mitochondria to 50 nmole CaCl2 pulses at 3-minute intervals.  
PTP induction was denoted by the inability of mitochondria to take up calcium (sharp 
increase in extramitochondrial calcium fluorescence).  Data were quantified as the 
amount of calcium needed to induce PTP opening (nmoles CaCl2/mg mitochondria).  
For experiments where redox state was manipulated, energized mitochondria were 
treated with either 200 µM diamide or 2 mM dithiothreitol (DTT) for the 10 minutes prior 
to and throughout each experimental protocol.  Previous work from our laboratory has 
indicated that this concentration of diamide can elicit oxidative stress by significantly 
lowering GSH/GSSG (35).  Others have shown that this concentration of DTT can act 
as a reducing agent and decrease the likelihood of PTP opening under oxidative 
conditions (63).   
 A sub-set of rats (for PTP experiments) was treated daily with the mitochondria-
targeted antioxidant, Bendavia (aka SS-31 in the literature).  In this sub-set of STZ-
induced diabetic rats and control rats, BendaviaTM (1.5 mg/kg in 0.9% saline) was 
injected (i.p.) daily for the 4 days prior to each mitochondrial isolation day. 
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 Data are presented as mean + SEM.  Statistical analyses were performed using 
one-way ANOVA or two-way ANOVA (as appropriate), with Newman-Keuls post-hoc 
analysis for comparison between groups.  The level of significance was established at P 
< 0.05. 
Results 
 Animal characteristics.  Rat body weights, heart weights (corrected for body 
weight) and fasting glucoses are presented in Table 2.1.  STZ treated rats had 
significantly lower body weights as well as lower heart weights when compared to non-
STZ treated rats (P<0.05).  In order to confirm diabetes in STZ treated rats, we 
measured fasting blood glucose.  STZ treated rats displayed significantly higher fasting 
glucose levels when compared to non-STZ treated rats (495 + 21.9 vs. 114 + 1.43, 
respectively; P<0.05). 
 Infarct size.  Infarct sizes and representative infarct pictures are presented in 
Figure 2.1. Langendorff-perfused hearts from STZ treated rats were more susceptible to 
IR injury, with infarct sizes of 60+4% of the area-at-risk (vs. 46+2% in non-diabetics; 
P<0.05). Administration of 5uM NIM811 (non-immunosuppressive derivative of 
cyclosporine A), 1nM Bendavia (mitochondria-targeted antioxidant) and 1 uM 
minocycline at the onset of reperfusion significantly reduced diabetic infarct sizes 
(P<0.05) and to the same extent as NIM811 and Bendavia treated non-diabetic animals 
(P>0.05).  
 Hemodynamics.  Hemodynamics are presented in Tables 2.2.  There were no 
significant differences in hemodynamic parameters before the ischemic period nor at 
the end of reperfusion (P>0.05).  During the baseline and at the end of reperfusion, left 
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ventricular developed pressure, maximal rates of contraction (+dP/dt) and relaxation (-
dP/dt), and coronary flow rates were similar between all groups.    
 Arrhythmia scores.  Arrhythmia scores are presented in Figure 2.2.  There were 
no differences in the incidence arrhythmias as measured by infarct size. 
 Respiratory control ratio.  Respiratory control ratios are presented in Figure 2.3.  
There were no differences in respiratory control ratios between mitochondria isolated 
from STZ and non-STZ treated rats (P>0.05), suggesting that the quality of 
mitochondrial preparation was not different between groups.  
 Calcium-induced PTP opening.  Fluorescence data for Ca-induced PTP opening 
as well as representative traces are depicted in Figure 2.4.  Isolated mitochondria from 
the left ventricle of STZ treated rats required significantly less calcium in order to induce 
PTP opening when compared to non-STZ treated rats (P<0.05), demonstrating that STZ 
treated rats have an enhanced sensitivity to Ca-induced PTP opening.  The enhanced 
sensitivity to PTP opening in STZ treated rats was significantly decreased (P<0.05) 
when isolated mitochondria were treated with 2 mM dithiothreitol or when animals 
received daily i.p. injections of 1.5 mg/kg Bendavia for the four days leading up to the 
experimental day.  However, treatment with DTT and Bendavia did not normalize Ca-
induced sensitivity to non-diabetic control levels.  Treatment with 200 uM diamide 
significantly increased the sensitivity to Ca-induced PTP opening in non-STZ treated 
rats (P<0.05) but had no effect on Ca-induced PTP sensitivity in STZ treated rats (vs. 
respective controls), suggesting that the redox state of diabetic isolated mitochondria 
can not be oxidized further.    
Discussion 
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 In this study, we hypothesized that the increased susceptibility to ischemia-
reperfusion (IR) injury observed in diabetes is due to an increased probability for 
mitochondrial permeability transition pore opening (PTP).  Moreover, we hypothesized 
that the increased propensity for PTP opening displayed by the diabetic heart was the 
result of an oxidative shift in the redox state.  The major findings of this work are 1) 
direct inhibition of PTP opening with NIM811 and indirect inhibition of PTP with 
Bendavia and minocycline significantly reduce infarct size in isolated diabetic hearts to 
the same extent as drug treated non-diabetic control hearts and 2) four days of 
treatment with Bendavia and treatment of isolated diabetic heart mitochondria with 
dithiothreitol significantly reduce the sensitivity to Ca-induced PTP opening.  To our 
knowledge, no previous study has described the cardioprotective effects of blocking 
PTP opening at the onset of reperfusion in diabetic animals.  Moreover, we are the first 
to show that a reductive shift in the redox state of isolated diabetic heart mitochondria 
decreases the sensitivity to Ca-induced PTP opening.   
Enhanced Sensitivity to PTP Explains Augmented IR Injury in Diabetic Hearts 
 Since first described nearly four decades ago (193), scores of investigators have 
attempted to uncover the mechanisms underlying diabetic cardiomyopathy [reviewed in 
(29, 30)].  Recently, an emerging body of evidence [reviewed in (41)] has pointed 
towards mitochondrial dysfunction as a potential culprit for the increased probability for 
death following myocardial infarction in these patients.  In particular, diabetic heart 
mitochondria display an enhanced propensity for PTP opening (8, 23, 174, 232), and 
PTP opening is widely accepted to be a distinctive feature of IR injury.  Because PTP 
opening is a hallmark of IR injury, inhibition of PTP opening provides substantial 
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protection against injury [reviewed in (96)].  However, until this work, no investigators 
had employed the use of PTP inhibition in diabetes to attenuate augmented myocardial 
IR injury. 
 Strategies that target cyclophilin D (CyP-D), a distinctive feature of the PTP, have 
been frequently employed to directly inhibit PTP opening (94-96).  A number of studies 
have indicated that inhibition of CyP-D with cyclosporine A (CsA) can decrease the 
probability of PTP opening and attenuate several indices of myocardial IR injury in non-
diabetic animals, including: infarction (10, 11, 101, 154, 228), left ventricular dysfunction 
(91, 102, 172), cardiomyocyte death (124, 165) and mitochondrial dysfunction (70, 173).  
In a recent clinical trial (182), the use of CsA at the time of reperfusion reduced infarct 
size in humans by approximately 30% (when assessed by MRI), corroborating previous 
data from animal studies.  Although promising, the use of CsA is confounded by a 
narrow therapeutic window (165), potentially harmful effects to the microvasculature 
(180, 214, 231), deleterious effects on long-term myocardial function (132), suppression 
of mitochondrial respiration (11), lack of protection against arrhythmia (4, 34), 
nephrotoxicity (163), and immunosuppression (15).  Due to the high rates of renal 
failure (2) and depressed immune function (157) in diabetic patients, we chose to 
employ the use of NIM811 to block PTP opening in isolated diabetic hearts.  NIM811 is 
a non-immunosuppressive derivative of CsA developed by Novartis, and unlike CsA, 
NIM811 blocks PTP formation by selectively binding matrix CyP-D and not the cytosolic 
immunosuppressant, cyclophilin A (222). It is widely accepted that CyP-D initiates PTP 
opening, and NIM811 has been shown to decrease infarct size and directly block Ca-
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induced PTP opening in intact non-diabetic rabbit hearts and isolated rabbit cardiac 
mitochondria, respectively (12), by specifically binding CyP-D.   
 A previous study demonstrated that the enhanced propensity for PTP opening in 
isolated diabetic heart mitochondria could be normalized to non-diabetic controls with 
CsA treatment (174).  In order to determine whether inhibition of PTP opening could 
attenuate myocardial IR injury in diabetic whole hearts to the same extent as non-
diabetic hearts, we utilized NIM811.  Corroborating previous reports (9, 69, 110, 129, 
144, 145, 199), we demonstrate that diabetic hearts are more susceptible to IR injury, 
as measured by a 30 percent increase in infarct size in our study.  The significance of 
our work is that directly inhibiting PTP opening with NIM811 at the onset of reperfusion 
attenuates infarct size to the same extent as NIM811 treated non-diabetic hearts, 
suggesting that the increased propensity for IR injury in diabetic hearts is due to an 
enhanced susceptibility to PTP opening.  
 In addition to directly blocking PTP opening by targeting CyP-D, several 
investigators have shown that indirectly inhibiting PTP opening by reducing the ROS 
burden (112, 168, 185) and/or mitochondrial Ca influx (190, 195) can attenuate 
myocardial IR injury in non-diabetic hearts.    Because the diabetic myocardium is 
characterized by an increased ROS burden (7), we hypothesized that the increase in 
oxidative stress associated with the diabetic heart may enhance the susceptibility to 
PTP opening and increase ischemic injury.  To determine if indirectly inhibiting PTP 
opening by scavenging mitochondrial ROS production decreases IR injury in diabetic 
hearts, we used the novel cell permeable compound Bendavia (SS31 in the literature).  
With its dimethyl-tyrosine residue and permeability properties, Bendavia is a 
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mitochondria-targeted scavenger of ROS (49).  In our experiments, we introduced 
Bendavia at the onset of reperfusion following a 20-minute period of global ischemia.  
Further, we show that indirect inhibition of PTP by decreasing mitochondrial Ca influx 
with minocycline also decreases cardiac IR injury in isolated diabetic hearts.  
Collectively, our data indicate that both direct and indirect inhibition of PTP opening 
attenuates IR injury as measured by a decrease in infarct size in isolated diabetic 
hearts.  Like NIM811, treatment with Bendavia and minocycline reduced infarct size in 
diabetic hearts to the same extent as drug treated non-diabetic control hearts.  These 
findings suggest that the increased susceptibility to IR injury in diabetic hearts is due to 
an enhanced susceptibility to PTP opening, mediated by an augmented ROS burden.  
Redox Modulated Changes in PTP Opening 
 There is scant evidence to explain the mechanisms responsible for the increased 
susceptibility to PTP opening in diabetic hearts.  Recently, two independent laboratories 
have demonstrated that CyP-D expression is elevated in diabetic hearts (142, 232), 
which could potentially explain a portion of the increased propensity for PTP opening.  
However, these studies did not consider potential post-translational mechanisms such 
as redox modifications that may alter the activity of CyP-D and lead to enhanced PTP 
opening.   In a recent investigation, human CyP-D was shown to be redox regulated 
(136).  In this study, Cys203 of CyP-D exhibited redox sensitivity, in that oxidation led to 
decreased isomerase activity and formation of an intramolecular disfulfide bridge with 
Cys157.  Several studies have shown that the diabetic heart displays an oxidative shift in 
redox state, characterized by increased reactive oxygen species (ROS) production (32, 
45, 128, 234) and a decreased capacity to buffer ROS (5, 148, 237) [also reviewed in 
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(41)].  Until this work, the link between oxidative stress and the enhanced sensitivity to 
Ca-induced PTP opening had not been established.  Our data are in accordance with 
previous studies conducted in both humans (8) and animal models of diabetes (23, 174, 
232), demonstrating that diabetic heart mitochondria have an enhanced sensitivity to 
PTP opening.  The novelty of our work is that the augmented sensitivity to Ca-induced 
PTP opening displayed by isolated diabetic heart mitochondria was significantly 
reduced when mitochondria were treated with the reducing agent, diothiothreitol (DTT) 
and when animals were treated with Bendavia intraperitoneally for four days.  Based on 
the observation that CyP-D activity can be redox modulated, it is tempting to speculate 
that CyP-D is more oxidized in diabetic heart mitochondria when compared to non-
diabetic controls.  Therefore, the potential mechanism for DTT and Bendavia-induced 
improvements may be due to redox modification of CyP-D.  However, future 
investigation is needed in order to support this hypothesis.   
 The Ca-induced sensitivity to PTP opening in diabetic mitochondria was not 
completely normalized with DTT or Bendavia.  One reason for this may have been that 
the reducing power of the DTT concentration used in our study may not have been 
enough to overcome the oxidized state of the redox sensitive PTP component.  
However, this seems unlikely due to the well known reducing capacity of DTT (74, 107, 
108).  Another possible explanation may be that a portion of the enhanced propensity 
for PTP opening in diabetic hearts is due to alterations in mitochondria-independent 
mechanisms, such as cell signaling pathways known to alter PTP opening [reviewed in 
(160)].  Although these pathways may be altered by redox state, they would not be 
present In our isolated mitochondrial preparation.  Nevertheless, the significant 
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decrease in sensitivity to PTP opening in diabetic heart mitochondria evoked by a 
reductive shift in redox state is a significant finding due to the fact that a reduction in the 
open probability of PTP has been shown to improve outcomes in patients with 
myocardial infarction (182).   
 In our study, DTT had no effect on the sensitivity to Ca-induced PTP opening in 
non-diabetic isolated heart mitochondria.  These data are in accordance with others (66) 
in that treatment with a reducing agent (DTT) can not decrease the sensitivity to Ca-
induced PTP opening unless conditions of oxidative stress are prevailing (63).  In 
addition, we demonstrate that the sensitivity to Ca-induced PTP opening was highly 
sensitive to treatment with diamide in isolated heart mitochondria from control but not 
diabetic animals.  Treatment with diamide enhanced the sensitivity to Ca-induced PTP 
opening in control animals to the same extent as non-treated and diamide treated 
diabetic heart mitochondria.  Taken together, these data support the hypothesis the 
oxiditaive shift in redox state characteristic of the diabetic heart is responsible for a 
portion of the enhanced sensitivity to PTP opening.    
Conclusions  
 In summary, these experiments provide evidence that the enhanced 
susceptibility to PTP opening in diabetic heart mitochondria explains the augmented 
myocardial ischemia-reperfusion injury observed.  In addition, the increased propensity 
for PTP opening characteristic of the diabetic heart is redox-dependent, and a reductive 
shift in redox state decreases the Ca-induced sensitivity to PTP opening.  
	  	  
Chapter 3 
Altered Mitochondrial Calcium Handling the Diabetic Heart 
Abstract 
 Many diabetic patients exhibit signs of heart failure, including both systolic and 
diastolic dysfunction, independent of coronary artery disease or hypertension.  Due to 
the key role of mitochondrial calcium (Ca) in supply-demand matching, impairments in 
mitochondrial calcium displayed by the diabetic heart have been implicated in 
myocardial dysfunction. The purpose of this study was to: 1) definitively determine if 
mitochondrial Ca influx via mitochondrial Ca uniporter (MCU) and efflux via 
mitochondrial Na-Ca exchanger are impaired in diabetes and 2) determine if redox-
dependent changes in mitochondrial Ca transients contribute to altered mitochondrial 
Ca handling in diabetic hearts.  Mitochondria isolated from the left ventricles of STZ-
induced diabetic rats displayed slower Ca uptake when compared to non-diabetic 
mitochondria (P<0.05), and Na/Ca exchange activity was faster in diabetic when 
compared to non-diabetic (P<0.05), despite no differences in respiratory control ratio or 
mitochondrial membrane potential between groups.  Treatment of diabetic mitochondria 
with 2mM of the reducing agent dithiothreitol significantly normalized MCU activity to 
non-diabetic levels. These findings suggest that diabetic heart mitochondria have 
reduced mitochondrial Ca content under physiological Ca concentrations and that the 
reduction in MCU activity is redox dependent.  Results from this study provide insight for 
the potential mechanisms underlying supply-demand mismatching in diabetic hearts.    
Introduction 
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 Approximately eight percent of the US population is diabetic (84), and by the year 
2025, it is estimated that the global population of diabetics will reach 300 million (125).  
Nearly 40 years ago, Rubler and colleagues observed manifestations of heart failure in 
patients suffering from diabetes, independent of coronary artery disease and 
hypertension (193).  Specifically, these investigators observed that diabetic patients had 
pathological left ventricular hypertrophy and myocardial fibrosis.  This heightened 
cardiac dysfunction observed in diabetic patients, independent of coronary artery 
disease or hypertension was termed diabetic cardiomyopathy (193).  Since that time, 
several other manifestations of diabetic cardiomyopathy have been observed.  
Presently, characteristics of diabetic cardiomyopathy include: systolic and diastolic 
dysfunction, left ventricular hypertrophy, impaired contractile reserve and interstitial 
fibrosis [reviewed in (30)].  Mechanisms underlying cardiac dysfunction in diabetics are 
still not clear.  This paucity in the literature provides a substantial barrier for the 
development of effective therapeutic strategies seeking to diminish heart failure in 
diabetic patients.  Elucidating the cellular mechanisms that contribute to the augmented 
cardiac dysfunction in the diabetic condition may foster novel treatments for diabetic 
patients that experience heart failure.   
 Many characteristics of idiopathic diabetic cardiomyopathy overlap with those of 
coronary artery disease/hypertension-induced heart failure in non-diabetic patients, 
including both systolic (75, 193) and diastolic dysfunction (33, 198, 200) as well as 
metabolic inflexibility (38, 147, 226).  While the pathogenesis of diabetic 
cardiomyopathy is likely due to a number of variables, an emerging body of evidence 
suggests that aberrant mitochondrial function plays a significant role in the cardiac 
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dysfunction observed in these patients [reviewed in (30, 41)].  Diabetic heart 
mitochondria exhibit impaired calcium (Ca) handling (80, 181, 215) coupled with an 
oxidative shift in redox state, characterized by increased reactive oxygen species (ROS) 
production (32, 45, 128, 234) and a decreased capacity to buffer ROS (5, 148, 237).  
Mitochondrial Ca is essential for cardiac function in that mitochondrial Ca serves as a 
nexus between myocardial supply and demand.  Mitochondrial Ca fluxes are integral to 
ATP supply and demand matching [reviewed in (89)].  Ca serves as a key activator for 
several NADH producing enzymes such as pyruvate dehydrogenase, isocitrate 
dehydrogenase, and α-ketoglutarate dehydrogenase (66, 99, 167).  In addition to 
activation of NADH production, there is evidence to support that Ca directly contributes 
to the activity of complex V of the mitochondrial electron transport system (217). Under 
physiological conditions, Ca enters the mitochondria chiefly through the mitochondrial 
calcium uniporter (MCU) and exits through the mitochondrial Na-Ca exchanger (mNCX) 
(189).     
Based on the bioenergetic importance of mitochondrial Ca, decrements in the 
activity of these mitochondrial Ca pathways may be responsible for the impaired cardiac 
function and decreased cardiac efficiency observed in both human (178, 179) and 
animal models of diabetes (31, 32). Because supply-demand mismatch is a 
distinguishing feature of clinical heart failure (60, 62, 166), it is logical that the impaired 
mitochondrial Ca handling observed in diabetes may be responsible for the cardiac 
dysfunction observed.  To date, there has been no mechanistic insight into the 
alterations observed in mitochondrial Ca handling.  Several investigators have shown 
that an oxidative shift in redox state can alter the activity of cytosolic Ca handling 
	   37	  	  
proteins (65, 218).  However, no laboratories have investigated the effects of the 
oxidative shift in redox state characteristic of the diabetic heart on mitochondrial Ca 
handling.  
 Here, we provide evidence that mitochondrial Ca influx is decreased via MCU 
and mitochondrial Ca efflux via mNCX is higher in isolated diabetic heart mitochondria.  
Further, we demonstrate that the impaired MCU activity in isolated diabetic heart 
mitochondria can be normalized to non-diabetic controls when treated with the     
reducing agent, dithiothreitol.  These observations suggest that the shift in redox state 
characteristic of the diabetic heart impairs mitochondrial Ca handling. 
Materials and Methods 
 All reagents used were of the highest grade commercially available (Sigma-
Aldrich, United States).  Calcium green 5N salt was purchased from Invitrogen 
(Carlsbad, CA, USA).     
 All animal studies were approved by the East Carolina University Institutional 
Animal Care and Use Committee and were in accordance with the principles stated in 
the Guide for the Care and Use of Laboratory Animals.  Male Sprague-Dawley rats (7-9 
weeks old) were housed in a temperature (22oC) and light-controlled (12 hour light/12 
hour dark) environment and fed standard rat chow (Research Diets, New Brunswick, 
NJ, USA) and water ad libitum.  
 After at least five days of acclimation to the facility, diabetes was induced with a 
single intraperitoneal (i.p.) injection of streptozotocin (STZ, 65 mg/kg) dissolved in 100 
mM sodium citrate (pH = 4.5) following a 12-hour overnight fast.  Control animals 
received an i.p. injection of sodium citrate.  All experiments were performed 2 weeks 
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following STZ injection.  Blood glucose was determined using a commercially available 
glucometer (One Touch Ultra 2, LifeScan, Milpitas, CA, USA 
 Cardiac mitochondria were isolated from the left ventricle of hearts utilizing a 
protocol similar to Boehm et al. (25).  For the mitochondrial isolation, all steps were 
performed at 4°C, and all instruments for the procedure were chilled overnight prior to 
the isolation at 4°C.  Rat hearts were excised from anesthetized rats (as described 
above) and immersed in 10 mL ice-cold isolation solution (IS) containing (in mM): 300 
sucrose, 10 sodium-hepes and 0.2 EDTA. The left ventricle was isolated, weighed, and 
rinsed in fresh IS buffer.  Hearts were minced into 2-3 cm3 cubes and subjected to 2 
minutes of digestion using 1.25 mg trypsin, diluted in 10 mL of IS (pH = 7.2).  Following 
digestion, 6.5 mg of trypsin inhibitor was added, diluted in 10 mL IS buffer + BSA 
(1mg/mL) at pH = 7.4.  Tissue was resuspended in 10 mL IS buffer + BSA and 
homogenized with a teflon Potter-homogenizer.  The homogenate was centrifuged at 
600g for 10 minutes, and the supernatant was then centrifuged at 8000g for 15 minutes.  
The supernatant was discarded, and the pellet re-suspended in 10 mL IS buffer + BSA.  
This step was repeated one more time, and the final pellet was stored on ice in ~150 mL 
IS buffer.  Mitochondrial protein content was determined using a BCA protein assay.  
 To determine the quality of our mitochondrial preparations, respiratory control 
ratios (RCR) were measured using a Clark-type micro-oxygen electrode 
(Microelectrodes, Bedford, NH, USA).  Reactions were conducted in a closed, 
magnetically stirred chamber in 2.5 mL mitochondria assay buffer containing (in mM): 
125 KCl, 5 HEPES, 2 K2PO4, 1 MgCl2 and 0.5 mg mitochondria (25o C, pH = 7.3).  
Following a two-minute equilibration period, mitochondria were energized with 5 mM 
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glutamate/5 mM malate to initiate state 2 respiration.  State 3 respiration was initiated 
with the addition of 2.5 mM ADP.  RCRs were calculated by dividing the state 3 
respiration by the state 2 respiration.   
 In a method similar to that used by Kamo et al. (117), mitochondrial membrane 
potential (ΔΨm) was determined based on the activity of the lipophilic cation, 
tetraphenylphosphonium (TPP+) using a TPP+ - selective electrode and a Ag/AgCl 
reference electrode (World Precision Instruments, Sarasota, FL, USA).  Changes in 
voltage were monitored on a Dell computer using commercially available software 
(Chart, AD Instruments, Colorado Springs, CO, USA). The ΔΨm was estimated from the 
equation: ΔΨm	  =	  58*log(v/V)	  –	  58*log(10FΔE/2.3RT-­‐1)	   (117),	  where	  ΔE, deflection in TPP+ 
voltage from baseline; R, gas constant; T, temperature; v, mitochondrial matrix volume; 
V, buffer volume. The baseline voltage was taken before addition of substrate, and 
mitochondrial matrix volume was assumed to be of 1µL/mg protein (191).  Based on a 
previous study (104), we assumed that matrix volumes were similar between STZ-
induced diabetic rats and non-diabetic rats.  For ΔΨm experiments, both the TPP+ - 
selective electrode and reference electrode were placed in a magnetically stirred 
chamber containing 2.5 mL mitochondria assay buffer (described above) and 0.5 mg 
mitochondria, supplemented with 1.2 µM TPP+.  Identical to RCR experiments, 
mitochondria were energized with 5 mM glutamate/5 mM malate.  State 3 respiration 
was initiated with the addition of 2.5 mM ADP.	  
 Mitochondria (0.75 mg) were suspended in mitochondria assay buffer (described 
above) and supplemented with the fluorescent probe 1 µM calcium green 5N salt (Ex = 
506 nm, Em = 532) to track changes in extramitochondrial calcium.  Fluorescence was 
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measured using a spectrophotometer (Photon Technology International, Birmingham, 
NJ, USA).  Mitochondrial calcium uniporter (MCU) and sodium-calcium exchanger 
(mNCX) activity experiments were performed under state 2 conditions, energized with 5 
mM glutamate/5 mM malate.  MCU activity was measured by adding a 50 nmole pulse 
of CaCl2 to mitochondria, and the disappearance of calcium from the extramitochondrial 
solution was monitored.  The disappearance of calcium was quantified by calculating 
the tau (time to 63% of baseline fluorescence).  mNCX activity was determined utilizing 
methods similar to those used in original works by Crompton and colleagues (55, 56).  
Specifically, mitochondria were loaded with 150 nmoles CaCl2.  Following the complete 
uptake of the calcium bolus and stabilization of extramitochondrial fluorescence, mNCX 
activity was initiated by the addition of 15 mM NaCl.  To quantify mNCX activity, the 
area under curve was calculated for the two minutes following addition of NaCl.  Two 
minutes was chosen because this is the time point where the mNCX-induced calcium 
extrusion reached a steady plateau.  For experiments where redox state was 
manipulated, energized mitochondria were treated with either 200 µM diamide or 2 mM 
dithiothreitol (DTT) for the 10 minutes prior to and throughout each experimental 
protocol.  Previous work from our laboratory has indicated that this concentration of 
diamide can elicit oxidative stress by significantly lowering GSH/GSSG (35).  Others 
have shown that this concentration of DTT can act as a reducing agent and decrease 
the likelihood of PTP opening under oxidative conditions (63). 
 Data are presented as mean + SEM.  Statistical analyses were performed using 
one-way ANOVA or two-way ANOVA (as appropriate), with Newman-Keuls post-hoc 
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analysis for comparison between groups.  The level of significance was established at P 
< 0.05. 
Results 
 Animal characteristics.  Rat body weights, heart weights (corrected for body 
weight) and fasting glucoses are presented in Table 2.1.  STZ treated rats had 
significantly lower body weights as well as lower heart weights when compared to non-
STZ treated rats (P<0.05).  In order to confirm diabetes in STZ treated rats, we 
measured fasting blood glucose.  STZ treated rats displayed significantly higher fasting 
glucose levels when compared to non-STZ treated rats (495 + 21.9 vs. 114 + 1.43, 
respectively; P<0.05). 
 Respiratory control ratio.  Respiratory control ratios are presented in Figure 2.3.  
There were no differences in respiratory control ratios between mitochondria isolated 
from STZ and non-STZ treated rats (P>0.05), suggesting that the quality of 
mitochondrial preparation was not different between groups.  
 MCU and mNCX activity.  Mitochondrial calcium uptake via MCU was 
significantly slower in isolated mitochondria from STZ treated rats when compared to 
non-STZ treated (Figure, 3.1; P<0.05) as measured by tau (time to 63% calcium 
uptake).  Further, mitochondrial calcium efflux via mNCX was significantly faster in STZ 
treated rats (vs. non-STZ treated rats, P<0.05; Figure 3.2).  The impairment in MCU 
activity observed in STZ treated isolated rat mitochondria was normalized to control with 
treatment of 2 mM dithiothreitol.   
 Mitochondrial membrane potential.  Mitochondrial membrane potentials are 
presented in Figure 2.3.  To rule out mitochondrial membrane potential as a potential 
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factor governing Ca transients, we used the TPP+-selective probe.  There were no 
differences in State 2 nor State 3 mitochondrial membrane potentials (P>0.05), 
suggesting no differences in the electrical driving force for Ca entry into mitochondria. 
Discussion 
 In this study, we hypothesized that impaired mitochondrial calcium (Ca) handling 
displayed by the diabetic heart is the result of an oxidative shift in the redox state of 
diabetic heart mitochondria.  The major findings of this work are 1) mitochondrial 
calcium influx through MCU is diminished in diabetic heart mitochondria 2) 
mitochondrial calcium efflux via mNCX is increased in isolated diabetic heart 
mitochondria 3) a reductive shift in redox state of isolated diabetic heart mitochondria 
normalizes mitochondrial Ca influx.  To our knowledge, we are the first to show that 
decreased mitochondrial Ca influx through MCU in diabetic hearts can be normalized 
with a reductive shift in redox state.   
It is widely accepted that mitochondrial Ca fluxes are integral to ATP supply and 
demand matching [reviewed in (89)].  Ca serves as a key activator for several NADH 
producing enzymes such as pyruvate dehydrogenase, isocitrate dehydrogenase, and α-
ketoglutarate dehydrogenase (66, 99, 167).  Because of the essential bioenergetic role 
of Ca in the myocardium, alterations in mitochondrial Ca fluxes can be detrimental to 
normal cardiac function and efficiency.  Under physiological conditions, Ca enters the 
mitochondria chiefly through the mitochondrial calcium uniporter (MCU) and exits 
through the mitochondrial Na-Ca exchanger (mNCX) [(189).  Previous studies have 
provided evidence that mitochondrial Ca influx was slower in isolated mitochondria from 
diabetic hearts (80, 181, 215).  Tanaka and colleagues demonstrated reduced Ca influx 
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into diabetic mitochondria.  However, the reduced mitochondrial Ca uptake observed in 
diabetic hearts was coupled with a decrease in mitochondrial membrane potential 
(ΔΨm).  Because ΔΨm is the primary driving force for mitochondrial Ca influx, a decrease 
in ΔΨm will decrease Ca influx into mitochondria.  Therefore, it is difficult to determine 
whether the difference in mitochondrial Ca influx observed in this study was solely due 
to decreased ΔΨm or if other factors were involved, such as altered expression of MCU 
or mNCX.  Moreover, the ΔΨm measurements were determined using the lipophilic 
cation TPMP+ in myocytes, which may have been influenced by reduced K+ repolarizing 
currents observed in diabetes (133).  Flarsheim and coworkers also demonstrated a 
reduction in mitochondrial Ca influx in diabetic rat hearts (80).  However, they did not 
measure ΔΨm in this study.  In addition, these observations were made using the Ca 
indicator, arsenazo III, which as been shown to enhance the production of ROS (155), 
and it has been observed that ROS can modulate the activity of other intracellular Ca 
handling proteins (65, 218).  Based on our findings and in light of these data, ROS 
induced by arsenazo III may have confounded the results of that study.   
In our mitochondrial Ca transient experiments, we directly observed Ca 
movements utilizing the fluorescent probe Ca-Green 5N, and to our knowledge, no 
other laboratories have shown that MCU activity can be altered by redox state in 
diabetic hearts.  Here, we substantiate the previous findings that mitochondrial Ca influx 
is slower in diabetic heart mitochondria, and this impairment is do to an oxidative shift in 
redox state.  However, like others (221), we did not observe differences in ΔΨm and can 
therefore rule out its electrical driving force as a causative factor for altered 
mitochondrial calcium transients.  It should be mentioned that we cannot rule out the 
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possibility of MCU differential expression between diabetic and non-diabetic heart 
mitochondria.  One potential explanation for the slower MCU activity in diabetic heart 
mitochondria might be due to decreased expression of MCU.  Until recently, the 
molecular identity of the MCU has remained elusive (18, 177).  In light of these new 
investigations, measurement of MCU expression in diabetic heart mitochondria is 
possible.  Determination of MCU expression in diabetic heart mitochondria will provide 
insight into the mechanisms responsible for decreased mitochondrial Ca influx.   
In addition to reduced MCU activity, we observed altered mNCX activity in 
mitochondria from diabetic hearts.  We found that mNCX activity is increased in STZ-
induced diabetic rat heart mitochondria, while Flarsheim and colleagues found no 
difference in activity for the same duration of diabetes (80).  One reason for these 
differences may be due to the fact that the ROS generation caused by arsenazo III used 
in their study may have abolished possible differences in mNCX activity. Another 
potential reason for these differences may be the fact we used 15 mM NaCl (as 
opposed to 10 mM NaCl by Flarsheim et al.) to induce Ca efflux via mNCX, and 15 mM 
NaCl induces greater Ca efflux from mitochondria than 10 mM (55, 56).  We chose this 
concentration because 15 mM NaCl has been shown to induce near maximal Ca efflux 
via mNCX (55) and may therefore allow us to see maximal differences.  Nevertheless, 
under our experimental conditions, we observed that isolated mitochondria from diabetic 
rat hearts display decreased MCU activity and increased mNCX activity.  Liu and 
O’Rourke observed that inhibition of mNCX with CGP-37157 can reverse decrements in 
NADH production in heart failure (138).  Taken together, these findings suggest that the 
increased mNCX activity observed in diabetic mitochondria in our study may lead to 
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bioenergetic compromise and explain a portion of the cardiac dysfunction observed in 
diabetes.    
From a mechanistic perspective, no investigators have explored the link between 
the oxidative shift in redox state characteristic of the diabetic heart and impaired 
mitochondrial Ca handling.  Here, we demonstrate that the impaired mitochondrial Ca 
influx through MCU can be rescued with DTT treatment, suggesting that an oxidative 
shift in the redox state of diabetic heart mitochondria is responsible for the impaired 
MCU activity.   These findings are significant because mitochondrial Ca influx is 
imperative for cardiac function, and improving mitochondrial influx via MCU may 
decrease the cardiac dysfunction observed in diabetic hearts. 
Our findings suggest that under physiological [Ca], Ca is low in diabetic heart 
mitochondria.  Extrapolating these in vitro findings to in vivo conditions, diabetic 
mitochondria would likely have less mitochondrial Ca.  Because increasing 
mitochondrial Ca levels leads to an increase in ATP synthesis, while decreasing 
mitochondrial Ca decreases ATP synthesis (115), it is plausible that the decreased MCU 
activity and increased mNCX activity observed in our study explain, at least in part, the 
cardiac dysfunction and inefficiency observed in diabetic hearts.    
Conclusions  
 In summary, these experiments provide evidence that mitochondrial Ca influx is 
slower in diabetic hearts while sodium-induced efflux of Ca is increased.  Further, MCU 
activity is redox-dependent and impaired mitochondrial Ca influx can be normalized with 
a reductive shift in redox state.  
	  	  
Chapter 4 
High Doses of Ketamine/xylazine Anesthesia Reduce Cardiac Ischemia- 
reperfusion Injury in Guinea Pigs 
Abstract 
Choosing an appropriate anesthetic protocol that will have minimal effect on the 
experimental design can be difficult.  Guinea pigs have highly variable responses to a 
variety of injectable anesthetics, including ketamine/xylazine (KX).  Because of this 
variability, supplemental doses are often required to obtain an adequate plane of 
anesthesia.  Our group is interested in studying the isolated guinea pig heart, and we 
must anesthetize guinea pigs prior to harvesting the heart.  In this study, we sought to 
determine if larger doses of KX protected isolated guinea pig hearts against myocardial 
ischemia/reperfusion injury.  Male Hartley guinea pigs, Crl:HA, (275-300g; n=14) were 
anesthetized with one of two doses of KX (Lower: K-85mg/kg, X-15 mg/kg or Higher: K-
200mg/kg, X-60mg/kg).  Following thoracotomy, hearts were subjected to 20 minutes of 
ischemia followed by 2 hours of reperfusion. The higher dose of KX significantly 
reduced myocardial infarct size when compared to the lower dose (36 ± 3 vs. 51 ± 6 %, 
respectively; P<0.05).  Further, the higher dose of KX improved hemodynamic function 
as measured by increases in both left ventricular developed pressure (49 + 4 vs. 30 + 8 
mmHg, respectively, P<0.05) and maximal rate of left ventricular relaxation (-876 + 70 
vs. -576 + 120 mmHg/sec, respectively, P<0.05), however, the higher dose of KX did 
not have an impact on the maximal rate of left ventricular contraction or coronary flow.  
In addition, the incidence of arrhythmias was unchanged by the higher dose of KX.  
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These results provide evidence that supplementation of KX to ensure an adequate 
anesthetic plane may introduce unwanted variability in ischemia/reperfusion studies.   
Introduction 
In many studies using animals, measurements collected on proteins, cells, or 
organs, must be done following proper anesthesia, but anesthetizing animals always 
comes with the caveat that the anesthesia itself may be inevitably altering the behavior 
of the system in question.  Choosing a suitable anesthesia protocol that will have 
minimal influence on the outcome measurements in a study while still providing an 
adequate plane of anesthesia, is an area of ongoing interest (209). 
Among laboratory animal models used in biomedical research, guinea pigs are 
known to have highly variable responses to a variety of anesthetic agents, particularly 
those injected both intraperitoneally and intramuscularly (13, 39, 58, 81, 88, 122, 184, 
208), however, the mechanism for this variation is not known.  Due to the variability in 
responsiveness from injections, and lack of a tail for intravenous delivery, many 
researchers prefer halogenated inhalation anesthetics (such as isoflurane, halothane, 
desflurane, enflurane or sevoflurane) for adequate anesthesia in guinea pigs.  While the 
use of volatile gas anesthetics is appropriate in many research disciplines, for 
investigators studying ischemia/reperfusion injury, all of these agents are 
contraindicated due to confounding effects of the anesthetics themselves.   For 
example, previous studies have shown that administration of volatile anesthetics 
confers protection against ischemia/reperfusion injury across species in tissues 
including heart (53, 61, 141, 183, 206), brain (119, 211, 225), kidney (116), lung (137) 
and liver (20).  Accordingly, many scientists interested in ischemia/reperfusion injury 
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employ various injectable drug classes as anesthetics.  One of the most common 
injectable anesthetics used for surgical procedures is a ketamine/xylazine (KX) 
combination, and the recommended KX dosage for guinea pigs varies considerably (30 
to 120 mg/kg for ketamine and 0.2 to 13 mg/kg for xylazine (77)).  This wide range likely 
reflects the difficulty in adequately anesthetizing guinea pigs for surgical procedures 
with KX (39), often necessitating supplemental injections (186).   
Our group is interested in cardiac ischemia/reperfusion injury, and when 
compared to other rodents such as the rat or mouse, the guinea pig is preferred 
because the electrophysiological profile of the guinea pig heart more closely resembles 
larger animals (35, 201), yet guinea pigs are easier to manage than larger mammals. 
Because the effect of KX on cardiac function and infarction is negligible compared to 
other means of anesthesia (53), KX is often utilized in cardiac experiments.  Consistent 
with other investigators (13, 58, 81, 88, 122, 184, 208), we have observed that the 
effectiveness of KX is highly variable among guinea pigs, and that supplemental 
injections of KX are often required in order to achieve an adequate surgical plane of 
anesthesia.  In previous studies, we anecdotally noticed that guinea pigs who required 
supplemental KX injections also appeared to have less cardiac damage after 
ischemia/reperfusion.  Given that we are focused on identifying novel treatments that 
protect the heart (34-39), variability introduced by the anesthetic regimen could 
significantly hinder the interpretation of our data.   
In this study we sought to determine if higher KX doses used to anesthetize our 
guinea pigs preconditioned isolated hearts against subsequent ischemic injury.  We 
hypothesized that hearts from animals receiving higher doses of KX would be protected 
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against experimental ischemia/reperfusion injury.  Here, we show that higher doses of 
KX significantly reduce myocardial infarct size and preserve hemodynamic function 
when compared to lower doses of KX.  
Materials and Methods 
A total of 14 male Hartley guinea pigs, Cavia porcellus, (275-300 g, 
approximately 30 days old) were obtained from a commercial vendor (Charles River 
Laboratories, Raleigh, NC). Based on health surveillance programs performed by the 
vendor and research institution, the guinea pigs were free from: Sendai virus, PVM, 
Reo, LCMV, GAV, Encephalitozoon cuniculi, Bordetella bronchiseptica, Streptococcus 
pneumoniae, S. zooepidemicus,  Klebsiella sp., Salmonella sp., ectoparasites, and 
endoparasites.  In order to minimize the effects of external stimuli, the following 
environmental conditions were maintained.  Animals were socially/group housed (3 -4) 
per cage in a room housing only that species.  The cages contained aspen bedding 
chips (Northeastern Products Corporation, Warrensburg, NY).  All animals were allowed 
a minimum of 5 days to acclimate following shipping prior to their experimental use.  
Standard guinea pig chow (Lab Diet ProLab 5P18, St. Louis, MO) was fed ad libitum 
and all animals were offered automatic water via lixits.  Environmental enrichment in the 
form of PVC tubes and vegetables were given to the guinea pigs.  Routine husbandry 
care was performed by the same husbandry technician, when possible, to help 
familiarize the animals to routine husbandry procedures.   
All research adhered to the principles stated in the Guide for the Care and Use of 
Laboratory Animals (169).  The protocol was approved by the East Carolina University 
Institutional Animal Care and Use Committee and was performed in a facility accredited 
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by the Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC), International.   
On each experimental day, animals were randomly assigned to one of two 
ketamine/xylazine anesthesia protocols as described in Table 3.1.  The lower dose 
protocol used in this study was recommended by the veterinary staff and is the typical 
dosage of KX used for surgical anesthesia in guinea pigs among investigators at our 
institution.  Although the lower dose protocol of KX (85/15 mg/kg) is at the higher range 
of dosages suggested (77), our previous experience indicated that as many as 3 
supplemental doses of the lower dose protocol were sometimes needed to achieve a 
surgical plane of anesthesia suitable for guinea pig thoracotomy, particularly following 
failure to achieve anesthesia with the initial dose.  For this reason and in consultation 
with the veterinary staff, we chose the concentrations of KX in the higher dose group 
(Table 3.1).  Each anesthetic cocktail was administered to the guinea pigs via 
intraperitoneal injection.  Fifteen minutes following KX injection, animals were tested for 
righting, toe-pinch, and corneal reflexes.  Animals in the lower dose group were without 
righting and corneal reflexes, however, we observed a toe-pinch reflex in several 
animals that received the lower dose KX (which would normally warrant a supplemental 
injection).  Therefore, because we sought to standardize the anesthetic dose for each 
animal to ascertain the effects on cardiac function, cervical dislocation was performed in 
all anesthetized animals immediately prior to thoracotomy to account for varied reflex 
responsiveness.  Cervical dislocation was performed in guinea pigs in a manner similar 
to the procedure for cervical dislocation in other rodents as described in the AVMA 2007 
euthanasia guidelines (1).  Fifteen minutes following i.p. injection of KX, cervical 
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dislocation was performed on anesthetized guinea pigs by a highly trained individual 
under the direct supervision of the attending veterinarian and with prior approval by the 
East Carolina University Institutional Animal Care and Use Committee. Although 
cervical dislocation was performed in 275-300g guinea pigs in this study (greater than 
the <200g recommendation for other rodents not under anesthesia), the dislocation was 
performed on anesthetized animals (who had no righting or corneal reflexes) and there 
were no complications with any of the animals.  Immediately following cervical 
dislocation, hearts were excised via midline thoracotomy. The aorta was secured 
around a cannula of a modified Langendorff apparatus (isolated perfused heart model) 
and retrogradely perfused (at 75 mmHg constant perfusion pressure) with buffer 
consisting of (in mM): 118 NaCl, 24 NaHCO3, 1.2 KH2PO4, 4.75 KCl, 1.2 MgSO4, 2.0 
CaCl2, and 10 glucose (equilibrated with 95/5 % O2/CO2), as described previously (35).  
A latex balloon (Harvard Apparatus Balloon size #6) was inserted through the mitral 
valve and into the left ventricle.  Cardiac hemodynamic and electrical parameters 
including: left ventricular developed pressure, perfusion pressure, coronary flow rates, 
maximal rates of contraction and relaxation, and volume-conducted electrocardiogram, 
were measured constantly throughout the protocol. These parameters of cardiac 
function were collected and digitized using the Powerlab System (A.D. Instruments Inc, 
USA & Canada), and stored on a personal computer for subsequent analysis. 
Following a 15 minute equilibration period, hearts were subjected to no-flow 
ischemia (global ischemia) for a period of 20 minutes.  Following the ischemic period, 
flow was re-established for a period of 2 hours (reperfusion). 
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At the end of the reperfusion period, hearts were cut down from the cannula, and 
the right ventricle and atria were removed.  In order to assess the amount of tissue 
death, infarct size was assessed histologically as previously described (36).  Briefly, the 
left ventricle was sliced into four slices from apex to base.  Each slice was weighed and 
incubated in a 1% 2,3,5-triphenyltetrazolium chloride (TTC) solution for 10 minutes in a 
slow shaking water bath (37o C). Measurement of infarct size using TTC staining is 
considered the gold standard for quantification of cardiac ischemia/reperfusion injury in 
numerous species, including dogs, rabbits, and rodents (78, 114, 228). Following the 
brief incubation, both sides of each slice were photographed with a digital camera 
associated with a dissecting microscope.  Infarct areas were quantified using computer 
software (ImageJ software, NIH, USA).  Total area at risk and infarct area were 
measured for each side of each slice and corrected for the wet weight of each slice.  All 
slices were averaged, and final infarct size was expressed as a percentage of the left 
ventricle. 
 Arrhythmias were characterized as previously described (34) using the guidelines 
established by the Lambeth Conventions and scored using a system similar to that 
described by Curtis and Walker (57). Arrhythmias were scored during the reperfusion 
period as follows: 0 = 0 – 49 ventricular premature beats; 1 = 50 – 499 ventricular 
premature beats; 2 = > 499 ventricular premature beats and/or 1 episode of 
spontaneously reverting ventricular tachycardia (VT) or ventricular fibrillation (VF) less 
than 60 sec in total duration; 3 = > 1 episode of VT or VF that is < 60 sec total duration; 
4 = reverting VT or VF or both that is < 120 s in total duration; 5 = VT or VT or both that 
is > 120 sec in combined duration; 6 = non-reverting (fatal) VT or VF that began 
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> 15 min after reperfusion; 7 = fatal VT/VF that began between 5 min and 15 min after 
reperfusion; 8 = fatal VT/VF that began less than 5 min after reperfusion.  In addition to 
arrhythmia scoring, total time in VT/VF was determined throughout reperfusion.   
 All data are presented as mean ± SEM.  A Student’s t-test was used to determine 
differences between groups, and statistical significance was established using an alpha 
level of 0.05. 
Results 
 Infarct size.  Representative infarct pictures and infarct size data are presented in 
Figure 4.1.  Following 20 minutes of ischemia and 2 hours of reperfusion, infarct size 
was significantly lower in hearts from animals receiving higher dose KX (n=7) when 
compared to the lower dose KX (n=7) treated animals (36 ± 3 vs. 51 ± 6 %, respectively; 
P<0.05).  This reduction in infarct size suggests that KX dose-dependently influences 
the development of cell death. 
   Hemodynamics.  There were no significant differences in hemodynamic 
parameters before the 20 minute ischemic period (Table 4.1).  During this baseline 
period, left ventricular developed pressure, maximal rates of contraction (+dP/dt) and 
relaxation (-dP/dt), and coronary flow rates were similar between the higher dose and 
lower dose KX groups.  Because normoxic hemodynamic function begins to decline in 
hearts after approximately 1.5 hours in our model (36), we examined hemodynamic 
differences between groups one hour into reperfusion.  One hour into the reperfusion 
period, there was a significant improvement in left ventricular developed pressure and 
maximal rate of relaxation in animals anesthetized with higher dose KX. There were no 
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significant differences between higher or lower dose KX groups in maximal rate of 
contraction or coronary flow during the reperfusion period (Table 1; P>0.05).  
 Electrocardiographic changes.  There were no observable differences in the 
incidence of reperfusion arrhythmias between higher dose and lower dose KX groups.  
Neither arrhythmia scores nor total time in ventricular tachycardia/fibrillation were 
influenced by the anesthetic regimen (data not shown).    
Discussion 
 This study was conducted to determine if higher doses of ketamine/xylazine (KX) 
anesthesia influenced cardiac ischemia/reperfusion injury. The variable tolerance of 
guinea pigs for KX anesthesia often leads to supplemental injections before surgical 
procedures can be performed, yet this supplementation of anesthetic may alter the 
physiology of the heart.  In this study, we show that higher dose KX reduces myocardial 
infarct size and preserves hemodynamic function in guinea pig hearts exposed to 
ischemia/reperfusion.  To the best of our knowledge, this is the first demonstration that 
higher doses of KX used to anesthetize guinea pigs protect the heart against ischemic 
injury. 
Anesthetic-induced Reduction in Infarct Size 
 The appropriate anesthesia protocol for animal studies is something that all 
laboratory animal veterinarians and investigators must take into consideration.  For 
scientists interested in studying ischemia/reperfusion injury, this task becomes 
considerably more complicated.  Inhalation agents are easy to administer and effective 
at providing anesthesia, yet are well known to confer protection against subsequent 
ischemia/reperfusion injury (also known as “preconditioning” the tissue against 
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infarction), reviewed in (61).  Anesthetic-induced preconditioning (with inhalants) is 
observed in a variety of tissues (20, 61, 116, 119, 183, 225) and in species ranging from 
laboratory mice (151), rats (119, 141), guinea pigs (187), rabbits (92), dogs (152, 227) 
and human patients undergoing surgery (20, 116).  
In cardiac ischemia/reperfusion studies, anesthesia, rather than euthanasia, is 
utilized to obtain a beating heart in order to avoid ischemic preconditioning, a 
phenomenon that has been extensively shown influence infarct size (19, 26, 239). In 
cardiac studies directly comparing the infarct-limiting effect of anesthetic regimens, 
inhalation anesthetics are the most robust in reducing infarct size when compared to 
injectable anesthetics (53, 224).  Due to the cardioprotection afforded by halogenated 
anesthetics, injectable anesthetics such as KX, pentobarbital or propofol are most 
frequently used in ischemia/reperfusion studies.  Among these injectable regimens, KX 
anesthesia exerts a smaller influence on infarct size than propofol or pentobarbital (53, 
92, 224).  Recent recommendations against the use of pentobarbital due to a narrow 
safety window and questions of efficacy (40, 203, 233) provide further support for KX 
anesthesia.  Lending additional support for the use of KX anesthesia, propofol is given 
intravenously and therefore can be difficult to administer in guinea pigs due to the 
difficulty associated with gaining IV access.  
 While KX appears to be an appropriate anesthetic regimen for 
ischemia/reperfusion studies, the difficulty attaining an adequate plane of anesthesia, 
especially in the guinea pig, frequently necessitates anesthetic supplementation (often 
multiple times) (39).  Although supplementing the anesthetic is very common (and often 
necessary to achieve an adequate surgical plane), the authors are not aware of any 
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reports where increasing the anesthetic dose was shown to alter ischemia/reperfusion 
injury.  In this study, we compared a higher dose to a lower dose of KX in the guinea pig 
and found that the higher KX dose reduced infarct size by approximately 30%, 
indicating that supplemental anesthetic KX doses may be introducing variability into 
experimental data by disproportionally preconditioning the tissue.   
Effect of KX Anesthesia on Cardiac Electrical/mechanical Function   
 In addition to examining the effect of varying KX doses on infarct size, we also 
examined the influence of higher dose KX on cardiac function. The absence of baseline 
differences in left ventricular function between higher and lower KX doses (Table 1) is 
consistent with previous reports showing that KX anesthesia had minimal effects on 
baseline pressure development (53).  This lack of influence on baseline cardiac function 
also provides support for KX use in cardiac functional studies given that volatile 
anesthetics are all potent negative inotropes (51-53, 71, 72, 118, 143, 149, 170, 171, 
194, 227, 229). 
Although different types of anesthetic drugs have been shown to influence 
recovery and incidence of arrhythmia (14, 156, 164, 235), we are not aware of studies 
that have examined the influence on post-ischemic functional recovery with a specific 
injectable anesthetic regimen.  Following ischemia, higher dose KX anesthesia 
preserved the pumping ability of the left ventricle (Table 3.1).  To the best of our 
knowledge, the finding that higher doses of KX influence the mechanical recovery of the 
heart during reperfusion is novel, and underscores the need for standardization of 
anesthetic agents (discussed below). The dose of KX used in anesthesia did not 
influence the propensity for ventricular arrhythmia in our study.  These findings are also 
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notable, as investigators who are primarily interested in cardiac electrophysiology may 
not need to be as concerned about the influence of KX anesthesia on propensity for 
arrhythmia.   
Effect of KX Anesthesia on Coronary Flow 
 In order to determine if differences in coronary perfusion could account for the 
cardioprotection we observed with high KX, we measured coronary flow rates from 
hearts in the study. Given that the xylazine is an agonist to α-2 adrenergic receptors, we 
postulated that the higher KX regimen may be constricting the coronary arteries and 
leading to hypoxic/ischemic preconditioning of the myocardium.  Higher doses of KX did 
not alter the coronary flow rate during the baseline period or reperfusion, indicating that 
the cardioprotection with higher KX doses is independent of altered cardiac perfusion.   
Standardization of the Anesthetic Regimen 
In terminal surgery studies where supplemental KX could confound the outcome 
variables, we propose an alternative means for tissue harvest.  The combination of KX 
followed by a physical method of euthanasia by appropriately trained individuals in 
anesthetized animals (K: 85 mg/kg and X: 15 mg/kg, as described in the Materials and 
Methods) successfully standardizes the dose of anesthetic while ensuring animals are 
rendered insensate prior to thoracotomy and heart removal.  It is important to note that 
this alternative is only applicable to terminal procedures where euthanasia is acceptable 
with regard to the experimental conditions.  In survival or in vivo studies where 
procedures are performed on anesthetized animals, the necessary supplementation to 
maintain a surgical plane of anesthesia may be unavoidable.  In this case, the need to 
document the amount of anesthetic administered to each animal is of primary 
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importance, and potential variability introduced by anesthetic supplementation must be 
acknowledged as a limitation to the experimental design.   
Although our study examined the effect of a higher KX dose on cardiac 
ischemia/reperfusion injury, we should note that higher doses of KX anesthesia may 
also alter infarct size in other tissues exposed to ischemia/reperfusion.  Similar to 
cardiac tissue, brain, liver, and kidney tissues may also be affected by higher doses of 
KX.  We suspect that like cardiac tissue, infarct size following ischemia may also be 
reduced in these tissues when supplemental KX doses are used during anesthesia, but 
future studies must be conducted to support this notion. 
Potential Mechanisms for Cardioprotection by Ketamine/Xylazine 
 In our study, we increased the dosage of both ketamine and xylazine and 
determined that in combination, KX acts as a cardioprotectant following 
ischemia/reperfusion injury.  While we cannot decipher the individual effects of higher 
ketamine or xylazine doses on myocardial ischemia/reperfusion injury, we will briefly 
speculate on mechanisms of action for each compound. Ketamine is a dissociative 
anesthetic that exerts its inhibitory actions by deactivating the N-methyl d-aspartate 
receptor (NMDAR), a non-selective cation channel. We are not aware of any studies 
directly examining the cardioprotective effects of ketamine, but ethanol, another 
NMDAR antagonist, has been shown to have cardioprotective properties (121, 175, 
212).  It is possible that increased glutamate release after NMDAR inhibition, which 
preconditions other tissues against cell death (196), was responsible for the reduction in 
ischemia/reperfusion injury observed in the higher dose KX group. Ketamine 
equilibrates into tissues rapidly, with a serum half-life of 13 minutes in rodents following 
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ip injection (150).  We cannot rule out the possibility that higher ketamine groups had 
greater heart uptake of ketamine, and that the protection observed may have involved 
higher tissue levels of ketamine.  However, a previous study administered ketamine 
immediately before ischemia and found that it had no effect on infarct size (158), 
arguing against a correlation between tissue ketamine levels and protection from 
infarction.    
Xylazine is both an analgesic and sedative, and has been shown to be an α2-
adrenergic agonist (44). Stimulation of α2-adrenergic receptors in heart leads to 
vasoconstriction, which might result in ischemic preconditioning of the tissue.  However, 
we saw no differences in baseline coronary flow rates between higher and lower KX 
doses, which suggests that any vasoconstricting properties of xylazine must be minimal 
and/or short-lived. Based on previous reports where increasing the xylazine content 
dose-dependently influenced cardiac function (236), and in other studies where treating 
with ketamine alone immediately prior to ischemia did not alter infarct size (158), it is 
tempting to speculate that increased doses of xylazine may be responsible for the 
cardioprotection observed in this study.   Future studies are needed to determine if 
increases in ketamine or xylazine alone contribute to cardioprotection, or if an increased 
combination of the two is necessary for cardioprotection (as observed herein). 
Study Limitations 
One limitation to our study is that there is no true control group, as all animals 
received KX prior to harvesting the heart.  While we cannot determine the extent of 
protection induced by the low-dose KX group compared to a “no-drug” group, we chose 
not to perform cervical dislocation on un-anesthetized animals to be in accordance with 
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AVMA guidelines on rodents greater than 200g (1). This limitation is also found in the 
literature, where studies comparing different anesthetics also have no true control group 
(53, 92, 158).  Among the studies contrasting different anesthetics, the magnitude of 
infarct-size reduction following KX anesthesia is modest, especially when comparing to 
volatile anesthetics that exert a much more profound influence on infarct size (53, 92).   
Furthermore, our study was specifically designed to test two distinct 
concentrations of KX.  Anesthetic supplementation with small incremental doses may 
not sufficiently precondition the heart as much as the wider range used herein, but it is 
clear that large differences in KX doses can substantially influence the susceptibility of 
the heart to injury.  Awareness of the potentially confounding effects of anesthetic 
supplementation, especially in animals where an adequate plane of anesthesia is 
difficult to achieve, should help investigators with the most accurate interpretation of 
their data.  It is not our purpose to suggest the use of the high dose protocol for 
anesthetizing guinea pigs, however, we want to emphasize the fact that the use of 
additional doses of KX can confound the interpretation of data obtained in cardiac 
ischemia/reperfusion studies.   
Conclusions 
In this study we found that higher doses of KX used to anesthetize guinea pigs 
led to a reduction in myocardial infarct size and led to improved hemodynamic function 
after experimental ischemia/reperfusion.  In studies examining ischemic injury, 
significant supplementation of KX to ensure adequate anesthesia in guinea pigs may be 





 This work has provided novel insight into the mechanisms underlying cardiac 
dysfunction and the enhanced susceptibility to death following myocardial infarction in 
diabetic patients.  In addition, this work has demonstrated that the anesthetic cocktail, 
ketamine-xylazine, can precondition the heart and provide protection against ischemia-
reperfusion (IR) injury.  This report provides support for the hypothesis that the 
augmented ischemic injury observed in diabetic patients is due to an enhanced 
propensity for mitochondrial permeability transition pore (PTP) opening.  Support for this 
hypothesis lies in the fact that direct and indirect inhibition of PTP opening at the onset 
of reperfusion following 20 minutes of ischemia in isolated diabetic rat hearts resulted in 
a significant decrease in infarct size.  Infarct size was reduced to the same extent in 
diabetic hearts when compared to non-diabetic hearts, suggesting that enhanced PTP 
opening is the primary factor governing augmented injury in the diabetic heart.  Perhaps 
of most clinical relevance, we introduced the use of three novel mitochondria-targeted 
therapies to achieve reduction in infarct size.  Because mitochondria appear to be one 
of the primary entities governing IR injury through induction of PTP, the ability of 
NIM811, Bendavia and minocycline to target mitochondria and inhibit PTP opening is 
ideal.   
 Coupled with an enhanced susceptibility to ischemic injury, diabetic patients 
exhibit several signs of heart failure, including: systolic and diastolic dysfunction, left 
ventricular hypertrophy and interstitial fibrosis, independent of coronary artery disease 
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or hypertension.  An emerging body of evidence has indicated that aberrant calcium 
(Ca) handling may be responsible for the manifestations of heart failure present in many 
diabetic individuals.  Calcium handling is required for the mechanical work performed by 
the heart as well as the mitochondrial ATP producing processes that support 
contraction.  In order to adequately support energy production with demand, 
mitochondrial Ca levels must be coordinated.  Ca enters the mitochondria down its 
electrochemical gradient through the mitochondrial Ca uniporter (MCU) and exits the 
mitochondria in a sodium-dependent manner via the Na-Ca exchanger (mNCX).  This 
work has illustrated that mitochondrial Ca handling is impaired in diabetic hearts.  
Specifically, mitochondrial Ca influx was decreased, while sodium-induced Ca efflux 
was increased.  These findings suggest that mitochondrial Ca may be low in diabetic 
hearts under physiological [Ca].  These findings compliment those of a recent study 
where inhibition of mNCX activity rescued heart failure (139).  Because a decrease in 
mitochondrial Ca can lead to bioenergetic compromise, the results of this work indicate 
that the cardiac dysfunction observed in diabetic patients may be due to impaired 
mitochondrial Ca handling, similar to that seen heart failure.     
 Taken together, the findings that diabetic heart mitochondria are able to retain 
less Ca via the activities of MCU and mNCX in the presence of enhanced sensitivity to 
Ca-induced PTP opening should not be misinterpreted.  To reference Dr. Andrew 
Halestrap, like Dr. Jekyll and Mr. Hyde, mitochondria possess two distinct personas: 
under physiological conditions, mitochondria utilize Ca to maintain ATP production in 
order to meet the cellular demand.  However, when overloaded with Ca, mitochondria 
summon their dark side and may induce necrotic and/or apoptotic cell death.  The 
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distinct role of mitochondria during physiological and pathological (i.e. ischemia-
reperfusion) conditions underscores the importance for careful regulation of 
mitochondrial Ca.  From a Teleological perspective, it is interesting to speculate that in 
the diabetic heart, mitochondria may be down regulating mitochondrial Ca levels in an 
attempt to decrease the likelihood of PTP opening and avoid cellular injury, since 
mitochondrial Ca overload is a significant contributor to PTP induction.  
 This work demonstrated that blocking mitochondrial Ca at the onset of 
reperfusion provided significant protection in both non-diabetic and diabetic isolated rat 
hearts subjected to a 20-minute ischemic insult.  While the acute use of mitochondrial 
Ca blockers may be a beneficial treatment during times of Ca overload in diabetic 
hearts, drugs such as minocycline may be detrimental to normal cardiac function.  The 
reduction in mitochondrial Ca observed in diabetic hearts may be further exacerbated 
with the use of minocycline.  Therefore, chronic use of minoclycline and/or other 
compounds that decrease mitochondrial calcium may need to be avoided in diabetic 
populations or other conditions characterized by bioenergetic compromise such as 
patients with heart failure. 
 Chapter 4 of this work was ancillary to the main body, however, it is significant in 
that ketamine-xylazine (KX) can precondition the heart and protect against IR injury.  
The implications of this study are that continuous supplementation of KX anesthesia 
often required in guinea pigs may introduce confounding results in IR injury studies.  
While we did not provide mechanistic insight into the cardioprotective properties of KX 
in our experiments, a recent study by Chang and colleagues revealed that ketamine can 
depress cytosolic Ca levels in hepatocytes (47) and therefore may be able to decrease 
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intracellular Ca overload.  However, the impact of ketamine on mitochondrial Ca was 
not revealed.  Based on the previously described relationship of cytosolic and 
mitochondrial Ca, these observations provide support for the hypothesis that that 
ketamine may decrease the likelihood of PTP opening by reducing cellular and 
mitochondrial overload of Ca.  
Future directions 
 In this work, we demonstrated that diabetic hearts are more susceptible to IR 
injury, and this increased propensity for IR injury was due to enhanced PTP opening.  
Further, PTP opening in isolated mitochondria from diabetic hearts was shown to be 
redox-modulated.  Because CyP-D has been shown to be redox-modulated, it would be 
interesting to determine if CyP-D is more oxidized in diabetic heart mitochondria when 
compared to non-diabetic and if this shift in redox state is associated with the enhanced 
propensity for PTP opening in diabetic hearts.  This determination could be made 
utilizing the redox western blotting technique and could provide insight into a potential 
therapeutic target in diabetic patients.  It would also be worthwhile to determine if MCU 
and mNCX are oxidized in diabetic hearts.  The present data would suggest that MCU 
in diabetic hearts is characterized by an oxidative shift in redox state.  Further, 
manipulation of mitochondrial Ca in isolated diabetic hearts exposed to varying 
workloads may provide insight into how mitochondrial Ca handling alters cardiac 
function in diabetes.  For instance, increasing mitochondrial Ca influx with spermine or 
decreasing mitochondrial efflux utilizing CGP-37157 may improve cardiac function in 
diabetic hearts.  While this work has provided many insights into the mechanisms 
underlying enhanced injury and cardiac dysfunction in diabetes, future investigation is 
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needed in order to gain additional insight and promote the development of therapeutic 
strategies seeking to mitigate these pathologies.      
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Figure 1.1 Time course of intracellular changes in rat myocardium during ischemia; 
ΔΨm, mitochondrial membrane potential; ΔΨp, sarcolemmal membrane potential; 
SarcKATP, sarcolemmal ATP-sensitive potassium channels; PTP, mitochondrial 
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Figure 1.2 Schematic of inner mitochondrial membrane depicting putative components 
of the permeability transition pore during normoxia; IMM, inner mitochondrial 
membrane; ANT, adenine nucleotide transferase; PiC, mitochondrial phosphate carrier; 
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Figure 1.3 Confirmation in isolated mitochondria that minocycline is just as effective as 
Ru360 at blocking mitochondrial calcium uptake via MCU; Ca, calcium; MCU, 
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Figure 1.4 Effect of Bendavia on infarct size in guinea pig hearts subjected to 20 
minutes of ischemia followed by 120 minutes of reperfusion.  Data are presented as 
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Figure 1.5 Schematic depiction of cytosolic and mitochondrial calcium transients in 
myocardium.  SR, sarcoplasmic reticulum; RyR, ryanodine receptor; SERCA, ATP-
dependent sarco/endoplasmic reticulum Ca-ATPase; MCU, mitochondrial calcium 
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Figure 1.6 Schematic depiction of the mitochondrial calcium circuit. IMM, inner 
mitochondrial membrane; OMM, outer mitochondrial membrane; MCU, mitochondrial 
calcium uniporter; mNCX, mitochondrial sodium-calcium exchanger; PTP, permeability 
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Figure 2.1 Representative infarct pictures and quantification of infarct sizes.  TTC 
stained viable tissue bright red, while infarcted tissue appears pale in color. Upper left, 
control; upper right, STZ; lower left STZ+NIM811; lower middle, STZ+Bendavia; lower 
right, STZ+minocycline; Control, non-diabetic rats; STZ, diabetic rats; data are 
presented as mean + SEM; *, P<0.05 versus non-drug treated control; #, P<0.05 versus 
non-drug treated STZ; N=5-10 in each group.        
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Figure 2.2 Representative trace of transition from normal sinus rhythm to ventricular 
fibrillation, as well as quantification of arrhythmia scores from isolated rat hearts 
following 20 minutes of ischemia and 120 minutes of reperfusion.  VF, ventricular 
fibrillation; Control, non-diabetic rats; STZ, diabetic rats; data are presented as mean + 
SEM.  There were no significant differences between groups, N=5-10 in each group.   
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Figure 2.3 Representative trace and quantification (next page) of mitochondrial 
membrane potential and respiratory control ratio from isolated heart mitochondria; there 
were no differences in State 2 or State 3 membrane potentials or respiratory control 
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Figure 2.3 continued 
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Figure 2.4 Representative fluorescence trace of Ca-induced PTP opening in STZ versus 
STZ+DTT isolated heart mitochondria as well as quantification (next page) of calcium 
retention capacity in isolated mitochondria. Control, non-diabetic; STZ, diabetic; DTT, 
dithiothreitol; PTP, permeability transition pore; *, P<0.05 versus non-drug treated 
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Figure 3.1 Representative trace and quantification of mitochondrial calcium uptake; 
Control, non-diabetic; STZ, diabetic; DTT, dithiothreitol; *, P<0.05 versus non-drug 
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Figure 3.2 Representative trace and quantification of mitochondrial sodium-induced 
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Figure 4.1 Representative infarct pictures and quantification of infarct sizes.  TTC 
stained viable tissue bright red, while infarcted tissue appears pale in color. Lower dose 
KX (left); Higher dose KX (right); IA, infarcted area; AAR, area at risk; KX, ketamine-
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Table 2.1 Animal characteristics.  BW, body weight; HW, heart weight; FG, fasting 
glucose; C, control; STZ, diabetic; *, P<0.05 versus control 
 
 
 C STZ 
BW (g) 348 + 6.8 307 + 12.4* 
HW/BW (mg/g) 5.29 + 0.12 4.44 + 0.17* 
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Table 2.2 Baseline and end of protocol hemodynamics. C, non-diabetic; STZ, diabetic; 
LVDP, left ventricular developed pressure; +dP/dt, maximal rate of left ventricular 
contraction; -dP/dt, maximal rate of left ventricular relaxation; CF, coronary flow.  Data 
are presented as mean + SEM; there were no significant differences between groups; 
N=5-10 in each group.        
 
Baseline Hemodynamics 
















Hemodynamics at the end of reperfusion 
 C  C+N C+B C+M STZ STZ+N STZ+B STZ+M 
LVDP  
(mmHg) 
30 + 7 22 + 4 34 + 3 36 + 6 26 + 3 25 + 3 24 + 4 32 + 9 
+dP/dt 
(mmHg/sec) 
768 + 96 734 + 101 913 + 216 1239 + 195 816 + 126 703 + 117 789 + 174 758 + 173 
-dP/dt 
(mmHg/sec) 
-535 + 63 -518 + 73 -704 + 63 -786 + 101 -489 + 63 -456 + 57 -475 + 75 -456 + 57 
CF  
(mL/min/g) 
3.8 + 0.4 2.5 + 0.3 3.7 + 0.2 4.1 + 0.2 4.3 + 0.7 3.7 + 0.2 4.0 + 0.6 4.3 + 0.8 
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Table 4.1 Doses of ketamine/xylazine used in the lower and higher dose groups and 
hemodynamic parameters of the guinea pig heart taken at baseline and one hour into 
reperfusion. K, ketamine; X, xylazine; LVDP, left ventricular developed pressure 
(mmHg); +dP/dt, maximal rate of left ventricular contraction (mmHg/sec); -dP/dt, 
maximal rate of left ventricular relaxation (mmHg/sec); coronary flow (mL/min/g wet 













     LVDP 
     +dP/dt  
     -dP/dt  
     Coronary Flow 
 
82 + 8 
1947 + 187 
-1512 + 146 
6.3 + 0.6 
 
96 + 10 
2138 + 97 
-1579 + 85 







      LVDP 
     +dP/dt 
     -dP/dt 
     Coronary Flow 
 
30 + 8 
833 + 186 
-576 + 120 
4.5 + 0.9 
 
49 + 5 
1190 + 94 
-876 + 70 
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